☰

Said M. Sebti - Publications

Affiliations: 
University of South Florida, Tampa, FL, United States 
Area:
Biochemistry, Cell Biology
Tree Info Similar researchers PubMed Report error

271 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2023 Kazi A, Ranjan A, Kumar M V V, Agianian B, Garcia Chavez M, Vudatha V, Wang R, Vangipurapu R, Chen L, Kennedy P, Subramanian K, Quirke JCK, Beato F, Underwood P, Fleming JB, ... ... Sebti SM, et al. Discovery of KRB-456, a KRAS G12D switch-I/II allosteric pocket binder that inhibits the growth of pancreatic cancer patient-derived tumors. Cancer Research Communications. PMID 38051103 DOI: 10.1158/2767-9764.CRC-23-0222  0.314
2021 Zhou L, Pei X, Zhang Y, Ning Y, Li L, Hu X, Chalasani SL, Sharma K, Nkwocha J, Yu J, Bandyopadhyay D, Sebti SM, Grant S. Chk1 inhibition potently blocks STAT3 tyrosine705 phosphorylation, DNA binding activity, and activation of downstream targets in human multiple myeloma cells. Molecular Cancer Research : McR. PMID 34782371 DOI: 10.1158/1541-7786.MCR-21-0366  0.341
2020 Yang H, Xiang S, Kazi A, Sebti SM. The GTPase KRAS suppresses the P53 tumor suppressor by activating the NRF2-regulated antioxidant defense system in cancer cells. The Journal of Biological Chemistry. PMID 32001619 DOI: 10.1074/Jbc.Ra119.011930  0.379
2019 Sebti SM, Kazi A, Xiang S, Yang H, Chen L, Kennedy P, Ayaz M, Fletcher S, Cummings C, Lawrence HR, Beato F, Kang Y, Kim MP, Delitto A, Underwood PW, et al. Dual farnesyl and geranylgeranyl transferase inhibitor thwarts mutant KRAS-driven patient-derived pancreatic tumors. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 31227505 DOI: 10.1158/1078-0432.Ccr-18-3399  0.302
2019 Kazi A, Xiang S, Yang H, Chen L, Kennedy P, Ayaz M, Fletcher S, Cummings C, Lawrence H, Beato F, Yang Y, Kim MP, Delitto A, Underwood P, Fleming JB, ... ... Sebti SM, et al. Abstract 3088: Farnesyl/geranylgeranyl transferase dual inhibitor thwarts mutant KRas-driven patient-derived pancreatic tumors Cancer Research. DOI: 10.1158/1538-7445.Sabcs18-3088  0.344
2018 Vangipurapu R, Chen L, Kennedy P, Morrison KC, Hergenrother PJ, Sebti SM. Abstract 1669: Identification of mutant KRas-Raf-1 binding disruptors Cancer Research. 78: 1669-1669. DOI: 10.1158/1538-7445.Am2018-1669  0.334
2017 Kuchay S, Giorgi C, Simoneschi D, Pagan J, Missiroli S, Saraf A, Florens L, Washburn MP, Collazo-Lorduy A, Castillo-Martin M, Cordon-Cardo C, Sebti SM, Pinton P, Pagano M. PTEN counteracts FBXL2 to promote IP3R3- and Ca(2+)-mediated apoptosis limiting tumour growth. Nature. PMID 28614300 DOI: 10.1038/Nature22965  0.33
2017 Nishimura S, Mishra-Gorur K, Park J, Surovtseva YV, Sebti SM, Levchenko A, Louvi A, Gunel M. Combined HMG-COA reductase and prenylation inhibition in treatment of CCM. Proceedings of the National Academy of Sciences of the United States of America. PMID 28500274 DOI: 10.1073/Pnas.1702942114  0.308
2017 Husain K, Centeno BA, Coppola D, Trevino J, Sebti SM, Malafa MP. d-Tocotrienol, a natural form of vitamin E, inhibits pancreatic cancer stem-like cells and prevents pancreatic cancer metastasis. Oncotarget. PMID 28404939 DOI: 10.18632/Oncotarget.15767  0.394
2017 Betts BC, Veerapathran A, Pidala J, Yang H, Horna P, Walton K, Cubitt CL, Gunawan S, Lawrence HR, Lawrence NJ, Sebti SM, Anasetti C. Targeting Aurora kinase A and JAK2 prevents GVHD while maintaining Treg and antitumor CTL function. Science Translational Medicine. 9. PMID 28077684 DOI: 10.1126/Scitranslmed.Aai8269  0.343
2017 Husain K, Sebti SM, Malafa MP. Abstract 1098: Delta-tocotrienol chemosensitizes human pancreatic tumor metastasis to gemcitabine targeting cancer stem cells Cancer Research. 77: 1098-1098. DOI: 10.1158/1538-7445.Am2017-1098  0.388
2016 Husain K, Coppola D, Sebti SM, Malafa MP. Abstract 3839: Vitamin E delta-tocotrienol targets human colon cancer stem cells and inhibits colon cancer metastasis and induces apoptosis Cancer Research. 76: 3839-3839. DOI: 10.1158/1538-7445.Am2016-3839  0.385
2015 Wang C, Husain K, Zhang A, Centeno BA, Chen DT, Tong Z, Sebti SM, Malafa MP. EGR-1/Bax pathway plays a role in vitamin E δ-tocotrienol-induced apoptosis in pancreatic cancer cells. The Journal of Nutritional Biochemistry. 26: 797-807. PMID 25997867 DOI: 10.1016/J.Jnutbio.2015.02.008  0.37
2015 Betts BC, Sagatys EM, Veerapathran A, Lloyd MC, Beato F, Lawrence HR, Yue B, Kim J, Sebti SM, Anasetti C, Pidala J. CD4+ T cell STAT3 phosphorylation precedes acute GVHD, and subsequent Th17 tissue invasion correlates with GVHD severity and therapeutic response. Journal of Leukocyte Biology. 97: 807-19. PMID 25663681 DOI: 10.1189/Jlb.5A1114-532Rr  0.333
2015 Li R, Cheng C, Balasis ME, Liu Y, Garner TP, Daniel KG, Li J, Qin Y, Gavathiotis E, Sebti SM. Design, synthesis and evaluation of marinopyrrole derivatives as selective inhibitors of Mcl-1 binding to pro-apoptotic Bim and dual Mcl-1/Bcl-xL inhibitors. European Journal of Medicinal Chemistry. 90: 315-31. PMID 25437618 DOI: 10.1016/J.Ejmech.2014.11.035  0.417
2015 Husain K, Sebti SM, Malafa MP. Abstract 4383: Vitamin E delta-tocotrienol inhibits metastasis and targets cancer stem cell signaling in human pancreatic cancer Cancer Research. 75: 4383-4383. DOI: 10.1158/1538-7445.Am2015-4383  0.387
2015 Yang H, Emmons MF, Cubitt C, Shain K, Coppola D, Sullivan D, Lynch CC, Hazlehurst L, Sebti SM. Abstract 2605: The geranylgeranyltransferase I inhibitor GGTI-2418 suppresses multiple myeloma malignancy in the 5TMG1 mouse model Cancer Research. 75: 2605-2605. DOI: 10.1158/1538-7445.Am2015-2605  0.357
2015 Kennedy PC, Guilanotti MC, LsVoi T, Sebti SM. Abstract 2580: Screening of a mixture-based synthetic combinatorial library identifies small molecules that inhibit the ability of GTP to displace mant-GDP from mutant G12D KRas Cancer Research. 75: 2580-2580. DOI: 10.1158/1538-7445.Am2015-2580  0.392
2015 Berndt N, Zhang X, Jiang RHY, Sebti SM. Abstract 2153: Kinome inhibitor screen identifies kinase inhibitors that inhibit selectively the survival of mutant K-Ras-dependent human cancer cells Cancer Research. 75: 2153-2153. DOI: 10.1158/1538-7445.Am2015-2153  0.476
2014 Tecleab A, Zhang X, Sebti SM. Ral GTPase down-regulation stabilizes and reactivates p53 to inhibit malignant transformation. The Journal of Biological Chemistry. 289: 31296-309. PMID 25210032 DOI: 10.1074/Jbc.M114.565796  0.794
2014 Kim YB, Kang CW, Ranatunga S, Yang H, Sebti SM, Del Valle JR. Imidazo[1,2-a]pyridine-based peptidomimetics as inhibitors of Akt. Bioorganic & Medicinal Chemistry Letters. 24: 4650-3. PMID 25205195 DOI: 10.1016/J.Bmcl.2014.08.040  0.388
2014 Cheng C, Liu Y, Balasis ME, Garner TP, Li J, Simmons NL, Berndt N, Song H, Pan L, Qin Y, Nicolaou KC, Gavathiotis E, Sebti SM, Li R. Marinopyrrole derivatives with sulfide spacers as selective disruptors of Mcl-1 binding to pro-apoptotic protein Bim. Marine Drugs. 12: 4311-25. PMID 25076060 DOI: 10.3390/Md12084311  0.379
2014 Zhang X, Blaskovich MA, Forinash KD, Sebti SM. Withacnistin inhibits recruitment of STAT3 and STAT5 to growth factor and cytokine receptors and induces regression of breast tumours British Journal of Cancer. 111: 894-902. PMID 24983364 DOI: 10.1038/Bjc.2014.349  0.398
2014 Teng P, Zhang X, Wu H, Qiao Q, Sebti SM, Cai J. Identification of novel inhibitors that disrupt STAT3-DNA interaction from a γ-AApeptide OBOC combinatorial library. Chemical Communications (Cambridge, England). 50: 8739-42. PMID 24964402 DOI: 10.1039/C4Cc03909B  0.333
2014 Yang H, Lawrence HR, Kazi A, Gevariya H, Patel R, Luo Y, Rix U, Schonbrunn E, Lawrence NJ, Sebti SM. Dual aurora a and jak2 kinase blockade effectively suppresses malignant transformation Oncotarget. 5: 2947-2961. PMID 24930769 DOI: 10.18632/Oncotarget.1615  0.486
2014 Cheng C, Liu Y, Balasis ME, Simmons NL, Li J, Song H, Pan L, Qin Y, Nicolaou KC, Sebti SM, Li R. Cyclic marinopyrrole derivatives as disruptors of Mcl-1 and Bcl-x(L) binding to Bim. Marine Drugs. 12: 1335-48. PMID 24608970 DOI: 10.3390/Md12031335  0.312
2014 Kazi A, Ozcan S, Tecleab A, Sun Y, Lawrence HR, Sebti SM. Discovery of PI-1840, a novel noncovalent and rapidly reversible proteasome inhibitor with anti-tumor activity Journal of Biological Chemistry. 289: 11906-11915. PMID 24570003 DOI: 10.1074/Jbc.M113.533950  0.806
2014 Patel RA, Liu Y, Wang B, Li R, Sebti SM. Identification of novel ROCK inhibitors with anti-migratory and anti-invasive activities Oncogene. 33: 550-555. PMID 23396364 DOI: 10.1038/Onc.2012.634  0.463
2014 Betts BC, Veerapathran A, Beato F, Lawrence HR, Sebti SM, Pidala JA, Anasetti C. CD4+ T-Cell STAT3 Activity Is Increased before Acute Graft-Versus-Host Disease Onset and Its Pharmacologic Inhibition Selectively Controls Alloresponses Blood. 124: 3819-3819. DOI: 10.1182/Blood.V124.21.3819.3819  0.314
2014 Aslamuzzaman K, Zhang X, Luo Y, Patel R, Fletcher S, Cummings C, Lawrence H, Hamilton A, Sebti SM. Abstract B35: Dual inhibitors of FT and GGT-1 as novel therapeutic agents for K-Ras-dependent tumors Molecular Cancer Research. 12. DOI: 10.1158/1557-3125.Rasonc14-B35  0.421
2014 Sebti SM, Berndt N, Patel R, Yang H, Balasis M. Abstract 4522: Akt2 and acid ceramidase cooperate to induce malignant transformation Cancer Research. 74: 4522-4522. DOI: 10.1158/1538-7445.Am2014-4522  0.452
2014 Zhang X, Blaskovich MA, Forinash KD, Sebti SM. Abstract 3802: Withacnistin blocks binding of STAT3 and STAT5 to growth factor and cytokine receptors and induces regression of breast tumors in vivo Cancer Research. 74: 3802-3802. DOI: 10.1158/1538-7445.Am2014-3802  0.412
2014 Sebti SM, Kazi A, Ozcan S, Tecleab AG, Sun Y, Lawrence H. Abstract 1810: PI-1840, a novel non-covalent and rapidly reversible proteasome inhibitor with anti-tumor activity Cancer Research. 74: 1810-1810. DOI: 10.1158/1538-7445.Am2014-1810  0.473
2014 Sebti SM, Yang H, Lawrence H, Kazi A, Gervaria H, Patel R, Luo Y, Rix U, Schonbrunn E, Lawrence N. Abstract 1750: Combined blockade of Aurora A and JAK2 kinase is highly effective at inhibiting malignant transformation Cancer Research. 74: 1750-1750. DOI: 10.1158/1538-7445.Am2014-1750  0.498
2014 Husain K, Sebti SM, Malafa MP. Abstract 1699: Delta-tocotrienol potentiates the antitumor activity of standard chemotherapy with gemcitabine and abraxane in metastatic pancreatic cancer Cancer Research. 74: 1699-1699. DOI: 10.1158/1538-7445.Am2014-1699  0.436
2014 Blaskovich MA, Luo Y, Ge Y, Sebti SM, Lawrence HR, Lawrence NJ, Springett GM. Abstract 1640: A novel small molecule inhibitor of lysophosphatidic acid acyltransferase-beta inhibits pancreatic cancer cell proliferation and mTOR signaling Cancer Research. 74: 1640-1640. DOI: 10.1158/1538-7445.Am2014-1640  0.402
2013 Blaskovich MA, Yendluri V, Lawrence HR, Lawrence NJ, Sebti SM, Springett GM. Lysophosphatidic acid acyltransferase beta regulates mTOR signaling. Plos One. 8. PMID 24205284 DOI: 10.1371/Journal.Pone.0078632  0.341
2013 Treviño JG, Verma M, Singh S, Pillai S, Zhang D, Pernazza D, Sebti SM, Lawrence NJ, Centeno BA, Chellappan SP. Selective disruption of rb-raf-1 kinase interaction inhibits pancreatic adenocarcinoma growth irrespective of gemcitabine sensitivity. Molecular Cancer Therapeutics. 12: 2722-34. PMID 24107447 DOI: 10.1158/1535-7163.Mct-12-0719  0.454
2013 Urlam MK, Pireddu R, Ge Y, Zhang X, Sun Y, Lawrence HR, Guida WC, Sebti SM, Lawrence NJ. Development of new N-Arylbenzamides as STAT3 Dimerization Inhibitors. Medchemcomm. 4: 932-941. PMID 24073326 DOI: 10.1039/C3Md20323A  0.302
2013 Sampath D, Malik A, Plunkett W, Nowak B, Williams B, Burton M, Verstovsek S, Faderl S, Garcia-Manero G, List AF, Sebti S, Kantarjian HM, Ravandi F, Lancet JE. Phase I clinical, pharmacokinetic, and pharmacodynamic study of the Akt-inhibitor triciribine phosphate monohydrate in patients with advanced hematologic malignancies. Leukemia Research. 37: 1461-7. PMID 23993427 DOI: 10.1016/J.Leukres.2013.07.034  0.403
2013 Husain K, Centeno BA, Chen DT, Hingorani SR, Sebti SM, Malafa MP. Vitamin E δ-tocotrienol prolongs survival in the LSL-KrasG12D/+;LSL-Trp53R172H/+;Pdx-1-Cre (KPC) transgenic mouse model of pancreatic cancer. Cancer Prevention Research (Philadelphia, Pa.). 6: 1074-83. PMID 23963802 DOI: 10.1158/1940-6207.Capr-13-0157  0.356
2013 Almhanna K, Cubitt CL, Zhang S, Kazim S, Husain K, Sullivan D, Sebti S, Malafa M. MK-2206, an Akt inhibitor, enhances carboplatinum/paclitaxel efficacy in gastric cancer cell lines. Cancer Biology & Therapy. 14: 932-6. PMID 23917345 DOI: 10.4161/Cbt.25939  0.348
2013 Berndt N, Patel R, Yang H, Balasis ME, Sebti SM. Akt2 and acid ceramidase cooperate to induce cell invasion and resistance to apoptosis. Cell Cycle (Georgetown, Tex.). 12: 2024-32. PMID 23777806 DOI: 10.4161/Cc.25043  0.446
2013 Schonbrunn E, Betzi S, Alam R, Martin MP, Becker A, Han H, Francis R, Chakrasali R, Jakkaraj S, Kazi A, Sebti SM, Cubitt CL, Gebhard AW, Hazlehurst LA, Tash JS, et al. Development of highly potent and selective diaminothiazole inhibitors of cyclin-dependent kinases. Journal of Medicinal Chemistry. 56: 3768-82. PMID 23600925 DOI: 10.1021/Jm301234K  0.395
2013 Ozcan S, Kazi A, Marsilio F, Fang B, Guida WC, Koomen J, Lawrence HR, Sebti SM. Oxadiazole-isopropylamides as potent and noncovalent proteasome inhibitors Journal of Medicinal Chemistry. 56: 3783-3805. PMID 23547706 DOI: 10.1021/Jm400221D  0.335
2013 Hodul PJ, Dong Y, Husain K, Pimiento JM, Chen J, Zhang A, Francois R, Pledger WJ, Coppola D, Sebti SM, Chen DT, Malafa MP. Vitamin E δ-tocotrienol induces p27(Kip1)-dependent cell-cycle arrest in pancreatic cancer cells via an E2F-1-dependent mechanism. Plos One. 8: e52526. PMID 23393547 DOI: 10.1371/Journal.Pone.0052526  0.45
2013 Tecleab A, Sebti SM. Depletion of K-Ras promotes proteasome degradation of survivin. Cell Cycle (Georgetown, Tex.). 12: 522-32. PMID 23324341 DOI: 10.4161/Cc.23407  0.777
2013 Husain K, Centeno BA, Chen DT, Fulp WJ, Perez M, Zhang Lee G, Luetteke N, Hingorani SR, Sebti SM, Malafa MP. Prolonged survival and delayed progression of pancreatic intraepithelial neoplasia in LSL-KrasG12D/+;Pdx-1-Cre mice by vitamin E δ-tocotrienol. Carcinogenesis. 34: 858-63. PMID 23302291 DOI: 10.1093/Carcin/Bgt002  0.341
2013 Ucar DA, Magis AT, He DH, Lawrence NJ, Sebti SM, Kurenova E, Zajac-Kaye M, Zhang J, Hochwald SN. Inhibiting the interaction of cMET and IGF-1R with FAK effectively reduces growth of pancreatic cancer cells in vitro and in vivo. Anti-Cancer Agents in Medicinal Chemistry. 13: 595-602. PMID 23272972 DOI: 10.2174/1871520611313040009  0.438
2013 Tecleab A, Zhang X, Sebti SM. Abstract 767: RalGTPase regulation of p53 and its contribution to malignant transformation. Cancer Research. 73: 767-767. DOI: 10.1158/1538-7445.Am2013-767  0.754
2013 Patel RA, Lui Y, Wang B, Li R, Sebti SM. Abstract 5556: Discovery of RKI-18, a small molecule that inhibits Rho kinases 1 and 2, migration and invasion of human tumors. Cancer Research. 73: 5556-5556. DOI: 10.1158/1538-7445.Am2013-5556  0.482
2013 Zhang X, Sun Y, Pireddu R, Yang H, Urlam MK, Lawrence HR, Guida WC, Lawrence NJ, Sebti SM. Abstract 3254: Discovery of S3I-1757, a STAT3-STAT3 dimerization disruptor that inhibits STAT3 activity, tumor survival, migration and invasion. Cancer Research. 73: 3254-3254. DOI: 10.1158/1538-7445.Am2013-3254  0.392
2013 Blaskovich MA, Gevariya H, Lawrence NJ, Sebti S, Springett G. Abstract 2470: Identification and evaluation of small molecule inhibitors of lysophosphatidic acid acyltransferase-beta. Cancer Research. 73: 2470-2470. DOI: 10.1158/1538-7445.Am2013-2470  0.362
2013 Husain K, Centeno B, Perez M, Dung-Tsa C, Sebti SM, Malafa MP. Abstract 2070: Natural vitamin E delta-tocotrienol combined with gemcitabine prolongs the survival, induces apoptosis, inhibits tumor growth, angiogenesis and oncogenic signaling in a transgenic mouse model of pancreatic cancer. Cancer Research. 73: 2070-2070. DOI: 10.1158/1538-7445.Am2013-2070  0.398
2012 Pireddu R, Forinash KD, Sun NN, Martin MP, Sung SS, Alexander B, Zhu JY, Guida WC, Schönbrunn E, Sebti SM, Lawrence NJ. Pyridylthiazole-based ureas as inhibitors of Rho associated protein kinases (ROCK1 and 2). Medchemcomm. 3: 699-709. PMID 23275831 DOI: 10.1039/C2Md00320A  0.397
2012 Gajewski TF, Salama AK, Niedzwiecki D, Johnson J, Linette G, Bucher C, Blaskovich MA, Sebti SM, Haluska F. Phase II study of the farnesyltransferase inhibitor R115777 in advanced melanoma (CALGB 500104). Journal of Translational Medicine. 10: 246. PMID 23228035 DOI: 10.1200/Jco.2006.24.18_Suppl.8014  0.377
2012 Kim YB, Balasis ME, Doi K, Berndt N, DuBoulay C, Hu CC, Guida W, Wang HG, Sebti SM, Del Valle JR. Synthesis and evaluation of substituted hexahydronaphthalenes as novel inhibitors of the Mcl-1/BimBH3 interaction. Bioorganic & Medicinal Chemistry Letters. 22: 5961-5. PMID 22901384 DOI: 10.1016/J.Bmcl.2012.07.050  0.398
2012 Ucar DA, Kurenova E, Garrett TJ, Cance WG, Nyberg C, Cox A, Massoll N, Ostrov DA, Lawrence N, Sebti SM, Zajac-Kaye M, Hochwald SN. Disruption of the protein interaction between FAK and IGF-1R inhibits melanoma tumor growth. Cell Cycle (Georgetown, Tex.). 11: 3250-9. PMID 22894899 DOI: 10.1093/Carcin/Bgr115  0.41
2012 Patel RA, Forinash KD, Pireddu R, Sun Y, Sun N, Martin MP, Schönbrunn E, Lawrence NJ, Sebti SM. RKI-1447 is a potent inhibitor of the Rho-associated ROCK kinases with anti-invasive and antitumor activities in breast cancer. Cancer Research. 72: 5025-34. PMID 22846914 DOI: 10.1158/0008-5472.Can-12-0954  0.453
2012 Lawrence HR, Martin MP, Luo Y, Pireddu R, Yang H, Gevariya H, Ozcan S, Zhu JY, Kendig R, Rodriguez M, Elias R, Cheng JQ, Sebti SM, Schonbrunn E, Lawrence NJ. Development of o-chlorophenyl substituted pyrimidines as exceptionally potent aurora kinase inhibitors. Journal of Medicinal Chemistry. 55: 7392-416. PMID 22803810 DOI: 10.1021/Jm300334D  0.366
2012 Caceres G, Robey RW, Sokol L, McGraw KL, Clark J, Lawrence NJ, Sebti SM, Wiese M, List AF. HG-829 is a potent noncompetitive inhibitor of the ATP-binding cassette multidrug resistance transporter ABCB1. Cancer Research. 72: 4204-13. PMID 22761337 DOI: 10.1158/0008-5472.Can-12-0743  0.341
2012 Cheng F, Wang H, Horna P, Wang Z, Shah B, Sahakian E, Woan KV, Villagra A, Pinilla-Ibarz J, Sebti S, Smith M, Tao J, Sotomayor EM. Stat3 inhibition augments the immunogenicity of B-cell lymphoma cells, leading to effective antitumor immunity. Cancer Research. 72: 4440-8. PMID 22728650 DOI: 10.1158/0008-5472.Can-11-3619  0.323
2012 Ginestier C, Monville F, Wicinski J, Cabaud O, Cervera N, Josselin E, Finetti P, Guille A, Larderet G, Viens P, Sebti S, Bertucci F, Birnbaum D, Charafe-Jauffret E. Mevalonate Metabolism Regulates Basal Breast Cancer Stem Cells and Is a Potential Therapeutic Target Stem Cells. 30: 1327-1337. PMID 22605458 DOI: 10.1002/Stem.1122  0.375
2012 Doi K, Li R, Sung SS, Wu H, Liu Y, Manieri W, Krishnegowda G, Awwad A, Dewey A, Liu X, Amin S, Cheng C, Qin Y, Schonbrunn E, Daughdrill G, ... ... Sebti S, et al. Discovery of marinopyrrole A (maritoclax) as a selective Mcl-1 antagonist that overcomes ABT-737 resistance by binding to and targeting Mcl-1 for proteasomal degradation. The Journal of Biological Chemistry. 287: 10224-35. PMID 22311987 DOI: 10.1074/Jbc.M111.334532  0.374
2012 Win-Piazza H, Schneeberger VE, Chen L, Pernazza D, Lawrence HR, Sebti SM, Lawrence NJ, Wu J. Enhanced anti-melanoma efficacy of interferon alfa-2b via inhibition of Shp2. Cancer Letters. 320: 81-5. PMID 22306001 DOI: 10.1016/J.Canlet.2012.01.034  0.369
2012 Li R, Martin MP, Liu Y, Wang B, Patel RA, Zhu JY, Sun N, Pireddu R, Lawrence NJ, Li J, Haura EB, Sung SS, Guida WC, Schonbrunn E, Sebti SM. Fragment-based and structure-guided discovery and optimization of Rho kinase inhibitors. Journal of Medicinal Chemistry. 55: 2474-8. PMID 22272748 DOI: 10.1021/Jm201289R  0.343
2012 Martin MP, Zhu JY, Lawrence HR, Pireddu R, Luo Y, Alam R, Ozcan S, Sebti SM, Lawrence NJ, Schönbrunn E. A novel mechanism by which small molecule inhibitors induce the DFG flip in Aurora A. Acs Chemical Biology. 7: 698-706. PMID 22248356 DOI: 10.1021/Cb200508B  0.388
2012 Ge Y, Kazi A, Marsilio F, Luo Y, Jain S, Brooks W, Daniel KG, Guida WC, Sebti SM, Lawrence HR. Discovery and synthesis of hydronaphthoquinones as novel proteasome inhibitors. Journal of Medicinal Chemistry. 55: 1978-98. PMID 22220566 DOI: 10.1021/Jm201118H  0.352
2012 Davis R, Pillai S, Lawrence N, Sebti S, Chellappan SP. TNF-α-mediated proliferation of vascular smooth muscle cells involves Raf-1-mediated inactivation of Rb and transcription of E2F1-regulated genes. Cell Cycle (Georgetown, Tex.). 11: 109-18. PMID 22185776 DOI: 10.4161/cc.11.1.18473  0.303
2012 Johnson JL, Pillai S, Pernazza D, Sebti SM, Lawrence NJ, Chellappan SP. Regulation of matrix metalloproteinase genes by E2F transcription factors: Rb-Raf-1 interaction as a novel target for metastatic disease. Cancer Research. 72: 516-26. PMID 22086850 DOI: 10.1158/0008-5472.Can-11-2647  0.307
2012 Pireddu R, Forinash K, Sun NN, Martin MP, Sung S, Alexander B, Zhu J, Guida WC, Schönbrunn E, Sebti SM, Lawrence NJ. Abstract 3904: Pyridylthiazole-based ureas as inhibitors of Rho-associated protein kinases Cancer Research. 72: 3904-3904. DOI: 10.1158/1538-7445.Am2012-3904  0.466
2012 Lawrence HR, Martin MP, Luo Y, Pireddu R, Gevariya H, Ozcan S, Zhu J, Rodriguez M, Elias R, Yang H, Sebti SM, Schonbrunn E, Lawrence NJ. Abstract 3902: Development of Aurora A inhibitors withortho-halophenyl substituted pyrimidines: Unusual potency, SAR and X-ray crystallography studies. Cancer Research. 72: 3902-3902. DOI: 10.1158/1538-7445.Am2012-3902  0.394
2012 Ozcan S, Kazi A, Sun NN, Daniel K, Guida WC, Lawrence HR, Sebti SM. Abstract 3894: Discovery, synthesis and SAR studies of a novel nonpeptidic reversible proteosome inhibitor with low nano-molar chymotrypsin like activity Cancer Research. 72: 3894-3894. DOI: 10.1158/1538-7445.Am2012-3894  0.419
2012 Patel RA, Forinash KD, Pireddu R, Sun Y, Martin MP, Zhu J, Alexander BG, Schonbrunn E, Lawrence NJ, Sebti SM. Abstract 2942: RKI-1447, a potent ROCK inhibitor with anti-tumor and anti-invasive activities in breast cancer Cancer Research. 72: 2942-2942. DOI: 10.1158/1538-7445.Am2012-2942  0.431
2012 Ge Y, Lawrence HR, Chen L, Scott LM, Sebti SM, Lawrence NJ, Wu J. Abstract 2912: Development of potent SHP2 inhibitors forin vivostudies Cancer Research. 72: 2912-2912. DOI: 10.1158/1538-7445.Am2012-2912  0.447
2012 Kazi A, Ozcan S, Lawrence H, Sebti SM. Abstract 2778: Development of non-covalent reversible proteasome inhibitors Cancer Research. 72: 2778-2778. DOI: 10.1158/1538-7445.Am2012-2778  0.472
2012 Blaskovich M, Gevariya H, Lawrence NJ, Sebti SM, Springett G. Abstract 1854: Lysophosphatidic Acid Acyltransferase-Beta contributes to proliferation and anchorage-independent growth in pancreatic adenocarcinoma Cancer Research. 72: 1854-1854. DOI: 10.1158/1538-7445.Am2012-1854  0.369
2012 Husain K, Centeno B, Perez M, Lee G, Kazim S, Chen D, Sebti S, Malafa M. Abstract 1613: Delta-tocotrienol delays the progression of pancreatic intraepithelial neoplasia (PanIN) lesions in a conditional KrasG12D mouse model Cancer Research. 72: 1613-1613. DOI: 10.1158/1538-7445.Am2012-1613  0.35
2011 Berndt N, Sebti SM. Measurement of protein farnesylation and geranylgeranylation in vitro, in cultured cells and in biopsies, and the effects of prenyl transferase inhibitors. Nature Protocols. 6: 1775-91. PMID 22036881 DOI: 10.1038/Nprot.2011.387  0.341
2011 Husain K, Francois RA, Yamauchi T, Perez M, Sebti SM, Malafa MP. Vitamin E δ-tocotrienol augments the antitumor activity of gemcitabine and suppresses constitutive NF-κB activation in pancreatic cancer. Molecular Cancer Therapeutics. 10: 2363-72. PMID 21971120 DOI: 10.1158/1535-7163.Mct-11-0424  0.374
2011 Balasis ME, Forinash KD, Chen YA, Fulp WJ, Coppola D, Hamilton AD, Cheng JQ, Sebti SM. Combination of farnesyltransferase and Akt inhibitors is synergistic in breast cancer cells and causes significant breast tumor regression in ErbB2 transgenic mice. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 17: 2852-62. PMID 21536547 DOI: 10.1158/1078-0432.Ccr-10-2544  0.452
2011 O'Neil BH, Goff LW, Kauh JS, Strosberg JR, Bekaii-Saab TS, Lee RM, Kazi A, Moore DT, Learoyd M, Lush RM, Sebti SM, Sullivan DM. Phase II study of the mitogen-activated protein kinase 1/2 inhibitor selumetinib in patients with advanced hepatocellular carcinoma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 2350-6. PMID 21519015 DOI: 10.1200/Jco.2010.33.9432  0.321
2011 Lancet JE, Duong VH, Winton EF, Stuart RK, Burton M, Zhang S, Cubitt C, Blaskovich MA, Wright JJ, Sebti S, Sullivan DM. A phase I clinical-pharmacodynamic study of the farnesyltransferase inhibitor tipifarnib in combination with the proteasome inhibitor bortezomib in advanced acute leukemias. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 17: 1140-6. PMID 21233404 DOI: 10.1158/1078-0432.Ccr-10-1878  0.319
2011 Scott LM, Chen L, Daniel KG, Brooks WH, Guida WC, Lawrence HR, Sebti SM, Lawrence NJ, Wu J. Shp2 protein tyrosine phosphatase inhibitor activity of estramustine phosphate and its triterpenoid analogs. Bioorganic & Medicinal Chemistry Letters. 21: 730-3. PMID 21193311 DOI: 10.1016/J.Bmcl.2010.11.117  0.394
2011 Garrett CR, Coppola D, Wenham RM, Cubitt CL, Neuger AM, Frost TJ, Lush RM, Sullivan DM, Cheng JQ, Sebti SM. Phase I pharmacokinetic and pharmacodynamic study of triciribine phosphate monohydrate, a small-molecule inhibitor of AKT phosphorylation, in adult subjects with solid tumors containing activated AKT. Investigational New Drugs. 29: 1381-9. PMID 20644979 DOI: 10.1007/S10637-010-9479-2  0.433
2011 Kazi A, Luo Y, Berndt N, Fletcher S, Cummings C, Lawrence H, Hamilton AD, Sebti SM. Abstract 620: Development of a dual protein farnesyltransferase -geranylgeranyltransferase-I inhibitor with antitumor activity against human cancer cells Cancer Research. 71: 620-620. DOI: 10.1158/1538-7445.Am2011-620  0.512
2011 Tecleab A, Sebti SM. Abstract 3844: K-Ras is required for maintaining survivin protein stability in human cancer cells harboring mutant but not wild type K-Ras Cancer Research. 71: 3844-3844. DOI: 10.1158/1538-7445.Am2011-3844  0.781
2011 Pireddu R, Lawrence HR, Martin MP, Betzi S, Yip R, Yang H, Sun NN, Cheng JQ, Schonbrunn E, Sebti SM, Lawrence NJ. Abstract 3253: Novel oxindole inhibitors of Aurora A kinase: Structure based hit-to-lead approach Cancer Research. 71: 3253-3253. DOI: 10.1158/1538-7445.Am2011-3253  0.426
2011 Luo Y, Martin M, Kendig R, Pireddu R, Yang H, Betzi S, Books W, Yu H, Schonbrunn E, Lawrence N, Cheng J, Sebti S, Lawrence H. Abstract 3252: Potent Aurora kinase inhibitors based on a pyrimidine scaffold: Synthesis, SAR and X-ray crystallography studies Cancer Research. 71: 3252-3252. DOI: 10.1158/1538-7445.Am2011-3252  0.405
2011 Gevariya H, Ortiz ED, Chen L, Daniel K, Lawrence HR, Guida WC, Sebti SM, Wu J, Lawrence NJ. Abstract 3248: New inhibitors of the Shp2 phosphatase Cancer Research. 71: 3248-3248. DOI: 10.1158/1538-7445.Am2011-3248  0.483
2011 Alexander BG, Pireddu R, Sun NN, Yu H, Forinash KD, Martin MP, Schonbrunn E, Guida WC, Sebti SM, Lawrence NJ. Abstract 3243: Discovery of novel Rho kinase inhibitors: Hit generation and lead optimization Cancer Research. 71: 3243-3243. DOI: 10.1158/1538-7445.Am2011-3243  0.394
2011 Pernazza D, Li X, Lawrence HR, Guida WC, DuBoulay CJ, Watts S, Sebti SM, Chen J, Lawrence NJ. Abstract 3242: New chemical tools for disrupting the MDM2/p53 protein-protein interaction: Identification, synthesis and biological evaluation of a novel class of MDM2/p53 inhibitors Cancer Research. 71: 3242-3242. DOI: 10.1158/1538-7445.Am2011-3242  0.418
2011 Scott LM, Chen L, Daniel KG, Urlam MK, Brooks WH, Guida WC, Lawrence HR, Sebti SM, Lawrence NJ, Wu J. Abstract 3239: Shp2 inhibitor activity of estramustine phosphate and its triterpenoid analogues Cancer Research. 71: 3239-3239. DOI: 10.1158/1538-7445.Am2011-3239  0.43
2011 Treviño JG, Verma M, Singh S, Pireddu R, Sebti S, Lawrence N, Chellappan SP. Abstract 2590: Selective disruption of Rb-Raf-1 kinase interaction is a suitable therapeutic option for pancreatic adenocarcinoma Cancer Research. 71: 2590-2590. DOI: 10.1158/1538-7445.Am2011-2590  0.319
2011 Verma M, Johnson J, Kovacs M, Singh S, Wu X, Lawrence N, Sebti S, Chellappan S. Abstract 2108: New analogues of benzyl-isothiourea showed Rb-Raf disruption and anti-cancer activity Cancer Research. 71: 2108-2108. DOI: 10.1158/1538-7445.Am2011-2108  0.476
2011 Blaskovich MA, Coppola D, Helm J, Sebti S, Springett GM. Abstract 1677: Expression of lysophosphatidic acid acyltransferase-beta in human pancreatic ductal adenocarcinoma Cancer Research. 71: 1677-1677. DOI: 10.1158/1538-7445.Am2011-1677  0.316
2011 Ge Y, Ozcan S, Kazi A, Marsilio F, Daniel K, Brooks W, Guida W, Lawrence H, Sebti S. Abstract 1362: Discovery of a novel structural class of compounds: HLM-030376 and its analogs as potent chymotrypsin-like proteasome inhibitors Cancer Research. 71: 1362-1362. DOI: 10.1158/1538-7445.Am2011-1362  0.457
2011 Ozcan S, Aslamuzzaman K, Marsilio F, Daniel K, Brooks W, Guida W, Lawrence H, Sebti S. Abstract 1359: Identification of a novel class of compounds as proteasome inhibitors: Synthesis and structure activity relationship studies of PI-1833 library Cancer Research. 71: 1359-1359. DOI: 10.1158/1538-7445.Am2011-1359  0.418
2011 Pernazza D, Doi K, Lawrence H, Sebti S, Wang H, Lawrence N. Abstract 1354: New chemical tools for disrupting the Mcl-1/BH3 protein-protein interaction Cancer Research. 71: 1354-1354. DOI: 10.1158/1538-7445.Am2011-1354  0.407
2011 Liu Y, Wang B, Patel RA, Sun N, Sung S, Pireddu R, Lawrence NJ, Sebti SM, Li R. Abstract A130: Fragment-based discovery and optimization of Rho kinase inhibitors. Molecular Cancer Therapeutics. 10. DOI: 10.1158/1535-7163.Targ-11-A130  0.371
2011 Berndt N, Hamilton AD, Sebti SM. Geranylgeranyltransferase-1 Inhibitors Enzymes. 30: 129-163. DOI: 10.1016/B978-0-12-415922-8.00006-9  0.348
2010 Singh S, Davis R, Alamanda V, Pireddu R, Pernazza D, Sebti S, Lawrence N, Chellappan S. Rb-Raf-1 interaction disruptor RRD-251 induces apoptosis in metastatic melanoma cells and synergizes with dacarbazine. Molecular Cancer Therapeutics. 9: 3330-41. PMID 21139044 DOI: 10.1158/1535-7163.Mct-10-0442  0.453
2010 Fletcher S, Keaney EP, Cummings CG, Blaskovich MA, Hast MA, Glenn MP, Chang SY, Bucher CJ, Floyd RJ, Katt WP, Gelb MH, Van Voorhis WC, Beese LS, Sebti SM, Hamilton AD. Structure-based design and synthesis of potent, ethylenediamine-based, mammalian farnesyltransferase inhibitors as anticancer agents. Journal of Medicinal Chemistry. 53: 6867-88. PMID 20822181 DOI: 10.1021/Jm1001748  0.371
2010 Lawrence HR, Kazi A, Luo Y, Kendig R, Ge Y, Jain S, Daniel K, Santiago D, Guida WC, Sebti SM. Synthesis and biological evaluation of naphthoquinone analogs as a novel class of proteasome inhibitors. Bioorganic & Medicinal Chemistry. 18: 5576-92. PMID 20621484 DOI: 10.1016/J.Bmc.2010.06.038  0.351
2010 Chen L, Pernazza D, Scott LM, Lawrence HR, Ren Y, Luo Y, Wu X, Sung SS, Guida WC, Sebti SM, Lawrence NJ, Wu J. Inhibition of cellular Shp2 activity by a methyl ester analog of SPI-112. Biochemical Pharmacology. 80: 801-10. PMID 20510203 DOI: 10.1016/J.Bcp.2010.05.019  0.471
2010 Scott LM, Lawrence HR, Sebti SM, Lawrence NJ, Wu J. Targeting protein tyrosine phosphatases for anticancer drug discovery Current Pharmaceutical Design. 16: 1843-1862. PMID 20337577 DOI: 10.2174/138161210791209027  0.341
2010 Mahajan K, Coppola D, Challa S, Fang B, Chen YA, Zhu W, Lopez AS, Koomen J, Engelman RW, Rivera C, Muraoka-Cook RS, Cheng JQ, Schönbrunn E, Sebti SM, Earp HS, et al. Ack1 mediated AKT/PKB tyrosine 176 phosphorylation regulates its activation. Plos One. 5: e9646. PMID 20333297 DOI: 10.1371/Journal.Pone.0009646  0.381
2010 Kim D, Sun M, He L, Zhou QH, Chen J, Sun XM, Bepler G, Sebti SM, Cheng JQ. A small molecule inhibits Akt through direct binding to Akt and preventing Akt membrane translocation. The Journal of Biological Chemistry. 285: 8383-94. PMID 20068047 DOI: 10.1074/Jbc.M109.094060  0.491
2010 Phan J, Li Z, Kasprzak A, Li B, Sebti S, Guida W, Schönbrunn E, Chen J. Structure-based design of high affinity peptides inhibiting the interaction of p53 with MDM2 and MDMX. The Journal of Biological Chemistry. 285: 2174-83. PMID 19910468 DOI: 10.1074/Jbc.M109.073056  0.374
2010 Caceres G, Robey RW, Sokol L, McGraw KR, Fulp WJ, Clark J, Lawrence NJ, Sebti S, Bates SE, List AF. In Vitro and In Vivo Inhibition of P-Glycoprotein (ABCB1) by a Novel Non-Substrate Compound: HG-829 Blood. 116: 3986-3986. DOI: 10.1182/Blood.V116.21.3986.3986  0.368
2010 Lawrence HR, Chen L, Pernazza D, Scott L, Ren Y, Luo Y, Wu X, Shen-Shu S, Guida W, Sebti SM, Lawrence NJ, Wu J. Abstract 761: The development of cell permeable Shp2 PTP inhibitors Cancer Research. 70: 761-761. DOI: 10.1158/1538-7445.Am10-761  0.444
2010 Wu X, Scott L, Chen L, Lawrence HR, Luo Y, Sebti SM, Wu J, Lawrence NJ. Abstract 734: Development of small molecule inhibitors of the phosphatase Shp2 by fragment screening Cancer Research. 70: 734-734. DOI: 10.1158/1538-7445.Am10-734  0.445
2010 Pireddu R, Sun NN, Yu H, Sung S, Sebti SM, Lawrence NJ. Abstract 733: Synthesis and biological evaluation of inhibitors of Rho protein kinase Cancer Research. 70: 733-733. DOI: 10.1158/1538-7445.Am10-733  0.438
2010 Pernazza D, Lawrence HR, Doi K, Sung S, Guida WC, Sebti SM, Wang H, Lawrence NJ. Abstract 732: Targeting the Bcl-2/BH3 protein-protein interaction: Identification, design, and synthesis of new selective inhibitors of the Mcl-1/BH3 interaction Cancer Research. 70: 732-732. DOI: 10.1158/1538-7445.Am10-732  0.412
2010 Husain K, Perez M, Sebti S, Malafa M. Abstract 5416: Delta-tocotrienol potentiates antitumor activity of gemcitabine in pancreatic cancer through inhibition of nuclear factor-κB Cancer Research. 70: 5416-5416. DOI: 10.1158/1538-7445.Am10-5416  0.423
2010 Berndt N, Yang H, Trinczek B, Zhang Z, Wu B, Lawrence NJ, Pellechia M, Schonbrunn E, Cheng JQ, Sebti SM. Abstract 3680: The Akt activation inhibitor TCN-P inhibits Akt phosphorylation by binding to the PH domain of Akt and blocking its recruitment to the plasma membrane Cancer Research. 70: 3680-3680. DOI: 10.1158/1538-7445.Am10-3680  0.439
2010 Yang H, Wang D, Hamilton AD, Sebti SM. Abstract 3675: Farnesyltransferase inhibitor (FTI) disruption of Rheb/FKBP38 association leads to FKBP38-mediated inactivation of mTOR Cancer Research. 70: 3675-3675. DOI: 10.1158/1538-7445.Am10-3675  0.513
2010 Zhang A, Francois RA, Hodul PJ, Husain K, Shivers SC, Coppola D, Sebti SM, Malafa MP. Abstract 222: Inhibition of cellular FLICE-inhibitory protein and induction of death receptor 5 expression is a major component of δ-tocotrienol-induced apoptosis in pancreatic cancer cells Cancer Research. 70: 222-222. DOI: 10.1158/1538-7445.Am10-222  0.384
2010 Husain K, Coppola D, Centeno B, Helm J, Kooman J, Lawrence N, Sebti S, Malafa M. Abstract 1612: Validation of CSE1L/hCAS as a potential therapeutic target in pancreatic cancer Cancer Research. 70: 1612-1612. DOI: 10.1158/1538-7445.Am10-1612  0.358
2009 O'Neil BH, Williams-Goff LW, Kauh J, Bekaii-Saab T, Strosberg JR, Lee R, Deal AM, Sullivan D, Sebti SM. A phase II study of AZD6244 in advanced or metastatic hepatocellular carcinoma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: e15574. PMID 27962385 DOI: 10.1200/Jco.2009.27.15_Suppl.E15574  0.313
2009 Hong DS, Sebti SM, Newman RA, Blaskovich MA, Ye L, Gagel RF, Moulder S, Wheler JJ, Naing A, Tannir NM, Ng CS, Sherman SI, El Naggar AK, Khan R, Trent J, et al. Phase I trial of a combination of the multikinase inhibitor sorafenib and the farnesyltransferase inhibitor tipifarnib in advanced malignancies. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 15: 7061-8. PMID 19903778 DOI: 10.1158/1078-0432.Ccr-09-1241  0.359
2009 Kazi A, Lawrence H, Guida WC, McLaughlin ML, Springett GM, Berndt N, Yip RM, Sebti SM. Discovery of a novel proteasome inhibitor selective for cancer cells over non-transformed cells. Cell Cycle (Georgetown, Tex.). 8: 1940-51. PMID 19471122 DOI: 10.4161/Cc.8.12.8798  0.445
2009 Lawrence HR, Li Z, Yip ML, Sung SS, Lawrence NJ, McLaughlin ML, McManus GJ, Zaworotko MJ, Sebti SM, Chen J, Guida WC. Identification of a disruptor of the MDM2-p53 protein-protein interaction facilitated by high-throughput in silico docking. Bioorganic & Medicinal Chemistry Letters. 19: 3756-9. PMID 19457663 DOI: 10.1016/J.Bmcl.2009.04.124  0.324
2009 Hast MA, Fletcher S, Cummings CG, Pusateri EE, Blaskovich MA, Rivas K, Gelb MH, Van Voorhis WC, Sebti SM, Hamilton AD, Beese LS. Structural basis for binding and selectivity of antimalarial and anticancer ethylenediamine inhibitors to protein farnesyltransferase. Chemistry & Biology. 16: 181-92. PMID 19246009 DOI: 10.1016/J.Chembiol.2009.01.014  0.37
2009 Kazi A, Carie A, Blaskovich MA, Bucher C, Thai V, Moulder S, Peng H, Carrico D, Pusateri E, Pledger WJ, Berndt N, Hamilton A, Sebti SM. Blockade of protein geranylgeranylation inhibits Cdk2-dependent p27Kip1 phosphorylation on Thr187 and accumulates p27Kip1 in the nucleus: implications for breast cancer therapy. Molecular and Cellular Biology. 29: 2254-63. PMID 19204084 DOI: 10.1128/Mcb.01029-08  0.772
2009 Kayser-Bricker KJ, Glenn MP, Lee SH, Sebti SM, Cheng JQ, Hamilton AD. Non-peptidic substrate-mimetic inhibitors of Akt as potential anti-cancer agents. Bioorganic & Medicinal Chemistry. 17: 1764-71. PMID 19179081 DOI: 10.1016/J.Bmc.2008.09.058  0.38
2009 Siddiquee KAZ, Gunning PT, Glenn M, Katt WP, Zhang S, Schrock C, Sebti SM, Jove R, Hamilton AD, Turkson J. An oxazole-based small-molecule stat3 inhibitor modulates stat3 stability and processing and induces antitumor cell effects (ACS Chemical Biology (2007) 2, (787-798)) Acs Chemical Biology. 4: 309. DOI: 10.1021/Cb9000684  0.341
2008 Chintala L, Kurzrock R, Fu S, Naing A, Wheler JJ, Moulder SL, Newman R, Gagel R, Sebti S, Wright JJ, Hong DS. Phase I study of tipifarnib and sorafenib in patients with biopsiable advanced cancer (NCI protocol 7156). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 26: 3593. PMID 27949369 DOI: 10.1200/Jco.2008.26.15_Suppl.3593  0.418
2008 Gunning PT, Glenn MP, Siddiquee KA, Katt WP, Masson E, Sebti SM, Turkson J, Hamilton AD. Targeting protein-protein interactions: suppression of Stat3 dimerization with rationally designed small-molecule, nonpeptidic SH2 domain binders. Chembiochem : a European Journal of Chemical Biology. 9: 2800-3. PMID 19006150 DOI: 10.1002/Cbic.200800291  0.359
2008 Fletcher S, Cummings CG, Rivas K, Katt WP, Hornéy C, Buckner FS, Chakrabarti D, Sebti SM, Gelb MH, Van Voorhis WC, Hamilton AD. Potent, Plasmodium-selective farnesyltransferase inhibitors that arrest the growth of malaria parasites: structure-activity relationships of ethylenediamine-analogue scaffolds and homology model validation. Journal of Medicinal Chemistry. 51: 5176-97. PMID 18686940 DOI: 10.1021/Jm800113P  0.373
2008 Lawrence HR, Pireddu R, Chen L, Luo Y, Sung SS, Szymanski AM, Yip ML, Guida WC, Sebti SM, Wu J, Lawrence NJ. Inhibitors of Src homology-2 domain containing protein tyrosine phosphatase-2 (Shp2) based on oxindole scaffolds. Journal of Medicinal Chemistry. 51: 4948-56. PMID 18680359 DOI: 10.1021/Jm8002526  0.379
2008 Gustafsdottir SM, Wennström S, Fredriksson S, Schallmeiner E, Hamilton AD, Sebti SM, Landegren U. Use of proximity ligation to screen for inhibitors of interactions between vascular endothelial growth factor A and its receptors. Clinical Chemistry. 54: 1218-25. PMID 18499900 DOI: 10.1373/Clinchem.2007.099424  0.312
2008 Kinkade R, Dasgupta P, Carie A, Pernazza D, Carless M, Pillai S, Lawrence N, Sebti SM, Chellappan S. A small molecule disruptor of Rb/Raf-1 interaction inhibits cell proliferation, angiogenesis, and growth of human tumor xenografts in nude mice. Cancer Research. 68: 3810-8. PMID 18483265 DOI: 10.1158/0008-5472.Can-07-6672  0.807
2008 Machida S, Usuba K, Blaskovich MA, Yano A, Harada K, Sebti SM, Kato N, Ohkanda J. Module assembly for protein-surface recognition: geranylgeranyltransferase I bivalent inhibitors for simultaneous targeting of interior and exterior protein surfaces. Chemistry (Weinheim An Der Bergstrasse, Germany). 14: 1392-401. PMID 18200641 DOI: 10.1002/Chem.200701634  0.335
2008 Elahi A, Zhang L, Yeatman TJ, Gery S, Sebti S, Shibata D. HPP1-mediated tumor suppression requires activation of STAT1 pathways. International Journal of Cancer. Journal International Du Cancer. 122: 1567-72. PMID 18059030 DOI: 10.1002/Ijc.23202  0.404
2008 Ravandi F, Sampath D, Plunkett W, Williams B, Burton M, Verstovsek S, Faderl S, Garcia-Manero G, Alvarez V, Becker MD, List AF, Sebti S, Kantarjian HM, Lancet J. Phase I Study of the Akt-Inhibitor Triciribine Phosphate Monohydrate in Patients with Advanced Hematologic Malignancy Blood. 112: 2987-2987. DOI: 10.1182/Blood.V112.11.2987.2987  0.363
2007 Siddiquee KA, Gunning PT, Glenn M, Katt WP, Zhang S, Schrock C, Schroeck C, Sebti SM, Jove R, Hamilton AD, Turkson J. An oxazole-based small-molecule Stat3 inhibitor modulates Stat3 stability and processing and induces antitumor cell effects. Acs Chemical Biology. 2: 787-98. PMID 18154266 DOI: 10.1021/Cb7001973  0.399
2007 Saglam O, Garrett CR, Boulware D, Sayegh Z, Shibata D, Malafa M, Yeatman T, Cheng JQ, Sebti S, Coppola D. Activation of the serine/threonine protein kinase AKT during the progression of colorectal neoplasia. Clinical Colorectal Cancer. 6: 652-6. PMID 17945038 DOI: 10.3816/Ccc.2007.N.034  0.417
2007 Falsetti SC, Wang DA, Peng H, Carrico D, Cox AD, Der CJ, Hamilton AD, Sebti SM. Geranylgeranyltransferase I inhibitors target RalB to inhibit anchorage-dependent growth and induce apoptosis and RalA to inhibit anchorage-independent growth. Molecular and Cellular Biology. 27: 8003-14. PMID 17875936 DOI: 10.1128/Mcb.00057-07  0.795
2007 Sagatys E, Garrett CR, Boulware D, Kelley S, Malafa M, Cheng JQ, Sebti S, Coppola D. Activation of the serine/threonine protein kinase Akt during the progression of Barrett neoplasia. Human Pathology. 38: 1526-31. PMID 17640711 DOI: 10.1016/J.Humpath.2007.03.003  0.407
2007 Siddiquee K, Zhang S, Guida WC, Blaskovich MA, Greedy B, Lawrence HR, Yip ML, Jove R, McLaughlin MM, Lawrence NJ, Sebti SM, Turkson J. Selective chemical probe inhibitor of Stat3, identified through structure-based virtual screening, induces antitumor activity. Proceedings of the National Academy of Sciences of the United States of America. 104: 7391-6. PMID 17463090 DOI: 10.1073/Pnas.0609757104  0.415
2007 Gunning PT, Katt WP, Glenn M, Siddiquee K, Siddique K, Kim JS, Jove R, Sebti SM, Turkson J, Hamilton AD. Isoform selective inhibition of STAT1 or STAT3 homo-dimerization via peptidomimetic probes: structural recognition of STAT SH2 domains. Bioorganic & Medicinal Chemistry Letters. 17: 1875-8. PMID 17336521 DOI: 10.1016/J.Bmcl.2007.01.077  0.365
2007 Epifano F, Curini M, Genovese S, Blaskovich M, Hamilton A, Sebti SM. Prenyloxyphenylpropanoids as novel lead compounds for the selective inhibition of geranylgeranyl transferase I Bioorganic and Medicinal Chemistry Letters. 17: 2639-2642. PMID 17314046 DOI: 10.1016/J.Bmcl.2007.01.097  0.341
2007 Kayser KJ, Glenn MP, Sebti SM, Cheng JQ, Hamilton AD. Modifications of the GSK3beta substrate sequence to produce substrate-mimetic inhibitors of Akt as potential anti-cancer therapeutics. Bioorganic & Medicinal Chemistry Letters. 17: 2068-73. PMID 17276059 DOI: 10.1016/J.Bmcl.2007.01.004  0.399
2007 Carie AE, Sebti SM. A chemical biology approach identifies a beta-2 adrenergic receptor agonist that causes human tumor regression by blocking the Raf-1/Mek-1/Erk1/2 pathway. Oncogene. 26: 3777-88. PMID 17260025 DOI: 10.1038/Sj.Onc.1210172  0.798
2007 Epling-Burnette PK, Sokol L, Moscinski L, Elkabani M, Bai F, Blaskovich M, Zou J, Painter JS, Sebti S, Loughran TP. First Clinical Report of Tipifarnib for the Treatment of T-Large Granular Lymphocyte (LGL) Leukemia. Blood. 110: 3132-3132. DOI: 10.1182/Blood.V110.11.3132.3132  0.308
2007 Wang H, Cheng F, Noyes D, Wright K, Mohapatra S, Tao J, Schell M, Sebti S, Smith M, Bhalla K, Pinilla J, Dessureault S, Celis D, Sotomayor EM, Sotomayor IbEM. Enhancement of the Antigen-Presenting Cell Function of Mantle Cell Lymphomas (MCL) by Novel Molecularly Based Immunotherapeutic Strategies. Blood. 110: 2315-2315. DOI: 10.1182/Blood.V110.11.2315.2315  0.338
2007 Bai F, Zou J-, Wei S, Painter JS, Blaskovich M, Sebti S, Loughran TP, Epling-Burnette PK. Th2 Polarization Induced by the Farnesyltransferase Inhibitor Tipifarnib (Zarnestra®, R115777) through Suppression of T-bet. Blood. 110: 1331-1331. DOI: 10.1182/Blood.V110.11.1331.1331  0.314
2006 Glenn MP, Chang SY, Hornéy C, Rivas K, Yokoyama K, Pusateri EE, Fletcher S, Cummings CG, Buckner FS, Pendyala PR, Chakrabarti D, Sebti SM, Gelb M, Van Voorhis WC, Hamilton AD. Structurally simple, potent, Plasmodium selective farnesyltransferase inhibitors that arrest the growth of malaria parasites. Journal of Medicinal Chemistry. 49: 5710-27. PMID 16970397 DOI: 10.1021/Jm060081V  0.348
2006 Hu B, Gilkes DM, Farooqi B, Sebti SM, Chen J. MDMX overexpression prevents p53 activation by the MDM2 inhibitor Nutlin. The Journal of Biological Chemistry. 281: 33030-5. PMID 16905541 DOI: 10.1074/Jbc.C600147200  0.411
2006 Sparano JA, Moulder S, Kazi A, Vahdat L, Li T, Pellegrino C, Munster P, Malafa M, Lee D, Hoschander S, Hopkins U, Hershman D, Wright JJ, Sebti SM. Targeted inhibition of farnesyltransferase in locally advanced breast cancer: a phase I and II trial of tipifarnib plus dose-dense doxorubicin and cyclophosphamide. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 24: 3013-8. PMID 16769985 DOI: 10.1200/Jco.2005.04.9114  0.323
2006 Zhou H, Wang DA, Baldini L, Ennis E, Jain R, Carie A, Sebti SM, Hamilton AD. Structure-activity studies on a library of potent calix[4]arene-based PDGF antagonists that inhibit PDGF-stimulated PDGFR tyrosine phosphorylation. Organic & Biomolecular Chemistry. 4: 2376-86. PMID 16763682 DOI: 10.1039/B515483A  0.774
2006 Tang D, Park HJ, Georgescu SP, Sebti SM, Hamilton AD, Galper JB. Simvastatin potentiates tumor necrosis factor alpha-mediated apoptosis of human vascular endothelial cells via the inhibition of the geranylgeranylation of RhoA. Life Sciences. 79: 1484-92. PMID 16740276 DOI: 10.1016/J.Lfs.2006.04.019  0.407
2006 Chen L, Sung SS, Yip ML, Lawrence HR, Ren Y, Guida WC, Sebti SM, Lawrence NJ, Wu J. Discovery of a novel shp2 protein tyrosine phosphatase inhibitor. Molecular Pharmacology. 70: 562-70. PMID 16717135 DOI: 10.1124/Mol.106.025536  0.471
2006 Donapaty S, Louis S, Horvath E, Kun J, Sebti SM, Malafa MP. RRR-alpha-tocopherol succinate down-regulates oncogenic Ras signaling. Molecular Cancer Therapeutics. 5: 309-16. PMID 16505104 DOI: 10.1158/1535-7163.Mct-05-0330  0.437
2005 Guida WC, Hamilton AD, Crotty JW, Sebti SM. Protein farnesyltransferase: flexible docking studies on inhibitors using computational modeling. Journal of Computer-Aided Molecular Design. 19: 871-85. PMID 16607571 DOI: 10.1007/S10822-005-9030-2  0.308
2005 Nefedova Y, Nagaraj S, Rosenbauer A, Muro-Cacho C, Sebti SM, Gabrilovich DI. Regulation of dendritic cell differentiation and antitumor immune response in cancer by pharmacologic-selective inhibition of the janus-activated kinase 2/signal transducers and activators of transcription 3 pathway. Cancer Research. 65: 9525-35. PMID 16230418 DOI: 10.1158/0008-5472.Can-05-0529  0.434
2005 Takahashi Y, Karbowski M, Yamaguchi H, Kazi A, Wu J, Sebti SM, Youle RJ, Wang HG. Loss of Bif-1 suppresses Bax/Bak conformational change and mitochondrial apoptosis. Molecular and Cellular Biology. 25: 9369-82. PMID 16227588 DOI: 10.1128/Mcb.25.21.9369-9382.2005  0.364
2005 Nefedova Y, Cheng P, Gilkes D, Blaskovich M, Beg AA, Sebti SM, Gabrilovich DI. Activation of dendritic cells via inhibition of Jak2/STAT3 signaling. Journal of Immunology (Baltimore, Md. : 1950). 175: 4338-46. PMID 16177074 DOI: 10.4049/Jimmunol.175.7.4338  0.376
2005 Turkson J, Zhang S, Mora LB, Burns A, Sebti S, Jove R. Platinum compounds that inhibit constitutive stat3 signaling and induce cell cycle arrest and apoptosis of malignant cells Journal of Biological Chemistry. 280: 32979-32988. PMID 16046414 DOI: 10.1074/Jbc.M502694200  0.318
2005 Glenn MP, Chang SY, Hucke O, Verlinde CL, Rivas K, Hornéy C, Yokoyama K, Buckner FS, Pendyala PR, Chakrabarti D, Gelb M, Van Voorhis WC, Sebti SM, Hamilton AD. Structurally simple farnesyltransferase inhibitors arrest the growth of malaria parasites. Angewandte Chemie (International Ed. in English). 44: 4903-6. PMID 16007716 DOI: 10.1002/Anie.200500674  0.304
2005 Chen L, Yin H, Farooqi B, Sebti S, Hamilton AD, Chen J. p53 alpha-Helix mimetics antagonize p53/MDM2 interaction and activate p53. Molecular Cancer Therapeutics. 4: 1019-25. PMID 15956260 DOI: 10.1158/1535-7163.Mct-04-0342  0.358
2005 Nallan L, Bauer KD, Bendale P, Rivas K, Yokoyama K, Hornéy CP, Pendyala PR, Floyd D, Lombardo LJ, Williams DK, Hamilton A, Sebti S, Windsor WT, Weber PC, Buckner FS, et al. Protein farnesyltransferase inhibitors exhibit potent antimalarial activity. Journal of Medicinal Chemistry. 48: 3704-13. PMID 15916422 DOI: 10.1021/Jm0491039  0.346
2005 Sun J, Wang DA, Jain RK, Carie A, Paquette S, Ennis E, Blaskovich MA, Baldini L, Coppola D, Hamilton AD, Sebti SM. Inhibiting angiogenesis and tumorigenesis by a synthetic molecule that blocks binding of both VEGF and PDGF to their receptors. Oncogene. 24: 4701-9. PMID 15897913 DOI: 10.1038/Sj.Onc.1208391  0.763
2005 Zuckerbraun BS, Barbato JE, Hamilton A, Sebti S, Tzeng E. Inhibition of geranylgeranyltransferase I decreases generation of vascular reactive oxygen species and increases vascular nitric oxide production1 Journal of Surgical Research. 124: 256-263. PMID 15820256 DOI: 10.1016/J.Jss.2004.10.022  0.308
2005 Mazières J, Tillement V, Allal C, Clanet C, Bobin L, Chen Z, Sebti SM, Favre G, Pradines A. Geranylgeranylated, but not farnesylated, RhoB suppresses Ras transformation of NIH-3T3 cells. Experimental Cell Research. 304: 354-64. PMID 15748883 DOI: 10.1016/J.Yexcr.2004.10.019  0.36
2005 Sun J, Blaskovich MA, Jove R, Livingston SK, Coppola D, Sebti SM. Cucurbitacin Q: a selective STAT3 activation inhibitor with potent antitumor activity. Oncogene. 24: 3236-45. PMID 15735720 DOI: 10.1038/sj.onc.1208470  0.336
2005 Zhu K, Gerbino E, Beaupre DM, Mackley PA, Muro-Cacho C, Beam C, Hamilton AD, Lichtenheld MG, Kerr WG, Dalton W, Alsina M, Sebti SM. Farnesyltransferase inhibitor R115777 (Zarnestra, Tipifarnib) synergizes with paclitaxel to induce apoptosis and mitotic arrest and to inhibit tumor growth of multiple myeloma cells. Blood. 105: 4759-66. PMID 15728126 DOI: 10.1182/Blood-2004-11-4307  0.345
2005 Wang DA, Sebti SM. Palmitoylated cysteine 192 is required for RhoB tumor-suppressive and apoptotic activities. The Journal of Biological Chemistry. 280: 19243-9. PMID 15713677 DOI: 10.1074/Jbc.M411472200  0.381
2005 Turkson J, Zhang S, Palmer J, Kay H, Stanko J, Mora LB, Sebti S, Yu H, Jove R. Inhibition of constitutive signal transducer and activator of transcription 3 activation by novel platinum complexes with potent antitumor activity. Molecular Cancer Therapeutics. 3: 1533-42. PMID 15634646  0.315
2005 Woo JT, Nakagawa H, Krecic AM, Nagai K, Hamilton AD, Sebti SM, Stern PH. Inhibitory effects of mevastatin and a geranylgeranyl transferase I inhibitor (GGTI-2166) on mononuclear osteoclast formation induced by receptor activator of NF kappa B ligand (RANKL) or tumor necrosis factor-alpha (TNF-alpha). Biochemical Pharmacology. 69: 87-95. PMID 15588717 DOI: 10.1016/J.Bcp.2004.08.036  0.385
2005 Cheng F, Wang H, Suarez A, Horna P, Sebti S, Sotomayor EM. Cucurbitacins, a Family of Natural Compounds That Effectively Disrupt Stat3 Signaling in Antigen-Presenting Cells (APCs) Are Promising Agents To Overcome Tumor-Induced CD4+ T-Cell Tolerance. Blood. 106: 1485-1485. DOI: 10.1182/Blood.V106.11.1485.1485  0.361
2004 Carrico D, Ohkanda J, Kendrick H, Yokoyama K, Blaskovich MA, Bucher CJ, Buckner FS, Van Voorhis WC, Chakrabarti D, Croft SL, Gelb MH, Sebti SM, Hamilton AD. In vitro and in vivo antimalarial activity of peptidomimetic protein farnesyltransferase inhibitors with improved membrane permeability. Bioorganic & Medicinal Chemistry. 12: 6517-26. PMID 15556768 DOI: 10.1016/J.Bmc.2004.09.020  0.398
2004 Epling-Burnette PK, Bai F, Wei S, Chaurasia P, Painter JS, Olashaw N, Hamilton A, Sebti S, Djeu JY, Loughran TP. ERK couples chronic survival of NK cells to constitutively activated Ras in lymphoproliferative disease of granular lymphocytes (LDGL). Oncogene. 23: 9220-9. PMID 15516985 DOI: 10.1038/Sj.Onc.1208122  0.384
2004 Dasgupta P, Sun J, Wang S, Fusaro G, Betts V, Padmanabhan J, Sebti SM, Chellappan SP. Disruption of the Rb--Raf-1 interaction inhibits tumor growth and angiogenesis. Molecular and Cellular Biology. 24: 9527-41. PMID 15485920 DOI: 10.1128/Mcb.24.21.9527-9541.2004  0.332
2004 Gasparetto M, Gentry T, Sebti S, O'Bryan E, Nimmanapalli R, Blaskovich MA, Bhalla K, Rizzieri D, Haaland P, Dunne J, Smith C. Identification of compounds that enhance the anti-lymphoma activity of rituximab using flow cytometric high-content screening. Journal of Immunological Methods. 292: 59-71. PMID 15350512 DOI: 10.1016/J.Jim.2004.06.003  0.312
2004 Paris D, Townsend K, Quadros A, Humphrey J, Sun J, Brem S, Wotoczek-Obadia M, DelleDonne A, Patel N, Obregon DF, Crescentini R, Abdullah L, Coppola D, Rojiani AM, Crawford F, ... Sebti SM, et al. Inhibition of angiogenesis by Abeta peptides. Angiogenesis. 7: 75-85. PMID 15302999 DOI: 10.1023/B:Agen.0000037335.17717.Bf  0.317
2004 Yang L, Dan HC, Sun M, Liu Q, Sun XM, Feldman RI, Hamilton AD, Polokoff M, Nicosia SV, Herlyn M, Sebti SM, Cheng JQ. Akt/protein kinase B signaling inhibitor-2, a selective small molecule inhibitor of Akt signaling with antitumor activity in cancer cells overexpressing Akt. Cancer Research. 64: 4394-9. PMID 15231645 DOI: 10.1158/0008-5472.Can-04-0343  0.468
2004 Jiang K, Sun J, Cheng J, Djeu JY, Wei S, Sebti S. Akt mediates Ras downregulation of RhoB, a suppressor of transformation, invasion, and metastasis. Molecular and Cellular Biology. 24: 5565-76. PMID 15169915 DOI: 10.1128/MCB.24.12.5565-5576.2004  0.317
2004 Sun J, Blaskovich MA, Jain RK, Delarue F, Paris D, Brem S, Wotoczek-Obadia M, Lin Q, Coppola D, Choi K, Mullan M, Hamilton AD, Sebti SM. Blocking angiogenesis and tumorigenesis with GFA-116, a synthetic molecule that inhibits binding of vascular endothelial growth factor to its receptor. Cancer Research. 64: 3586-92. PMID 15150116 DOI: 10.1158/0008-5472.Can-03-2673  0.414
2004 Mazieres J, Antonia T, Daste G, Muro-Cacho C, Berchery D, Tillement V, Pradines A, Sebti S, Favre G. Loss of RhoB expression in human lung cancer progression. Clinical Cancer Research. 10: 2742-2750. PMID 15102679 DOI: 10.1158/1078-0432.Ccr-03-0149  0.385
2004 Turkson J, Kim JS, Zhang S, Yuan J, Huang M, Glenn M, Haura E, Sebti S, Hamilton AD, Jove R. Novel peptidomimetic inhibitors of signal transducer and activator of transcription 3 dimerization and biological activity. Molecular Cancer Therapeutics. 3: 261-9. PMID 15026546  0.342
2004 Dan HC, Jiang K, Coppola D, Hamilton A, Nicosia SV, Sebti SM, Cheng JQ. Phosphatidylinositol-3-OH kinase/AKT and survivin pathways as critical targets for geranylgeranyltransferase I inhibitor-induced apoptosis. Oncogene. 23: 706-15. PMID 14737105 DOI: 10.1038/Sj.Onc.1207171  0.486
2004 Alsina M, Fonseca R, Wilson EF, Belle AN, Gerbino E, Price-Troska T, Overton RM, Ahmann G, Bruzek LM, Adjei AA, Kaufmann SH, Wright JJ, Sullivan D, Djulbegovic B, Cantor AB, ... ... Sebti SM, et al. Farnesyltransferase inhibitor tipifarnib is well tolerated, induces stabilization of disease, and inhibits farnesylation and oncogenic/tumor survival pathways in patients with advanced multiple myeloma. Blood. 103: 3271-7. PMID 14726402 DOI: 10.1182/Blood-2003-08-2764  0.415
2004 Ohkanda J, Buckner FS, Lockman JW, Yokoyama K, Carrico D, Eastman R, de Luca-Fradley K, Davies W, Croft SL, Van Voorhis WC, Gelb MH, Sebti SM, Hamilton AD. Design and synthesis of peptidomimetic protein farnesyltransferase inhibitors as anti-Trypanosoma brucei agents. Journal of Medicinal Chemistry. 47: 432-45. PMID 14711313 DOI: 10.1021/Jm030236O  0.406
2004 Jiang K, Delarue FL, Sebti SM. EGFR, ErbB2 and Ras but not Src suppress RhoB expression while ectopic expression of RhoB antagonizes oncogene-mediated transformation Oncogene. 23: 1136-1145. PMID 14647415 DOI: 10.1038/Sj.Onc.1207236  0.415
2003 Sebti SM, Der CJ. Opinion: Searching for the elusive targets of farnesyltransferase inhibitors. Nature Reviews. Cancer. 3: 945-51. PMID 14737124 DOI: 10.1038/Nrc1234  0.417
2003 Sun J, Ohkanda J, Coppola D, Yin H, Kothare M, Busciglio B, Hamilton AD, Sebti SM. Geranylgeranyltransferase I inhibitor GGTI-2154 induces breast carcinoma apoptosis and tumor regression in H-Ras transgenic mice. Cancer Research. 63: 8922-9. PMID 14695209  0.304
2003 Sebti SM. Blocked Pathways: FTIs Shut Down Oncogene Signals Oncologist. 8: 30-38. PMID 14671226 DOI: 10.1634/Theoncologist.8-Suppl_3-30  0.504
2003 Buckner F, Yokoyama K, Lockman J, Aikenhead K, Ohkanda J, Sadilek M, Sebti S, Van Voorhis W, Hamilton A, Gelb MH. A class of sterol 14-demethylase inhibitors as anti-Trypanosoma cruzi agents. Proceedings of the National Academy of Sciences of the United States of America. 100: 15149-53. PMID 14657358 DOI: 10.1073/Pnas.2535442100  0.312
2003 Santucci R, Mackley PA, Sebti S, Alsina M. Farnesyltransferase Inhibitors and Their Role in the Treatment of Multiple Myeloma Cancer Control. 10: 384-387. PMID 14581893 DOI: 10.1177/107327480301000505  0.357
2003 Zhang Z, Wang Y, Lantry LE, Kastens E, Liu G, Hamilton AD, Sebti SM, Lubet RA, You M. Farnesyltransferase inhibitors are potent lung cancer chemopreventive agents in A/J mice with a dominant-negative p53 and/or heterozygous deletion of Ink4a/Arf. Oncogene. 22: 6257-65. PMID 13679864 DOI: 10.1038/Sj.Onc.1206630  0.344
2003 Forsberg M, Blomgran R, Lerm M, Särndahl E, Sebti SM, Hamilton A, Stendahl O, Zheng L. Differential effects of invasion by and phagocytosis of Salmonella typhimurium on apoptosis in human macrophages: Potential role of Rho-GTPases and Akt Journal of Leukocyte Biology. 74: 620-629. PMID 12960245 DOI: 10.1189/Jlb.1202586  0.418
2003 Kurzrock R, Kantarjian HM, Cortes JE, Singhania N, Thomas DA, Wilson EF, Wright JJ, Freireich EJ, Talpaz M, Sebti SM. Farnesyltransferase inhibitor R115777 in myelodysplastic syndrome: clinical and biologic activities in the phase 1 setting. Blood. 102: 4527-34. PMID 12947010 DOI: 10.1182/Blood-2002-11-3359  0.337
2003 Peng Y, Li C, Chen L, Sebti S, Chen J. Rescue of mutant p53 transcription function by ellipticine. Oncogene. 22: 4478-87. PMID 12881704 DOI: 10.1038/Sj.Onc.1206777  0.354
2003 Blaskovich MA, Sun J, Cantor A, Turkson J, Jove R, Sebti SM. Discovery of JSI-124 (cucurbitacin I), a selective Janus kinase/signal transducer and activator of transcription 3 signaling pathway inhibitor with potent antitumor activity against human and murine cancer cells in mice. Cancer Research. 63: 1270-9. PMID 12649187  0.361
2003 Bolick SC, Landowski TH, Boulware D, Oshiro MM, Ohkanda J, Hamilton AD, Sebti SM, Dalton WS. The farnesyl transferase inhibitor, FTI-277, inhibits growth and induces apoptosis in drug-resistant myeloma tumor cells. Leukemia. 17: 451-7. PMID 12592346 DOI: 10.1038/Sj.Leu.2402832  0.45
2003 Doisneau-Sixou SF, Cestac P, Chouini S, Carroll JS, Hamilton AD, Sebti SM, Poirot M, Balaguer P, Faye JC, Sutherland RL, Favre G. Contrasting effects of prenyltransferase inhibitors on estrogen-dependent cell cycle progression and estrogen receptor-mediated transcriptional activity in MCF-7 cells. Endocrinology. 144: 989-98. PMID 12586776 DOI: 10.1210/En.2002-220726  0.319
2003 Mazzocca A, Giusti S, Hamilton AD, Sebti SM, Pantaleo P, Carloni V. Growth inhibition by the farnesyltransferase inhibitor FTI-277 involves Bcl-2 expression and defective association with Raf-1 in liver cancer cell lines. Molecular Pharmacology. 63: 159-66. PMID 12488548 DOI: 10.1124/Mol.63.1.159  0.479
2002 Allal C, Pradines A, Hamilton AD, Sebti SM, Favre G. Farnesylated RhoB prevents cell cycle arrest and actin cytoskeleton disruption caused by the geranylgeranyltransferase I inhibitor GGTI-298. Cell Cycle (Georgetown, Tex.). 1: 430-7. PMID 12548020 DOI: 10.4161/Cc.1.6.272  0.349
2002 Jackson RJ, Adnane J, Coppola D, Cantor A, Sebti SM, Pledger WJ. Loss of the cell cycle inhibitors p21(Cip1) and p27(Kip1) enhances tumorigenesis in knockout mouse models. Oncogene. 21: 8486-97. PMID 12466968 DOI: 10.1038/Sj.Onc.1205946  0.383
2002 Crespo NC, Delarue F, Ohkanda J, Carrico D, Hamilton AD, Sebti SM. The farnesyltransferase inhibitor, FTI-2153, inhibits bipolar spindle formation during mitosis independently of transformation and Ras and p53 mutation status. Cell Death and Differentiation. 9: 702-9. PMID 12058275 DOI: 10.1038/Sj.Cdd.4401023  0.74
2002 Ohkanda J, Knowles DB, Blaskovich MA, Sebti SM, Hamilton AD. Inhibitors of protein farnesyltransferase as novel anticancer agents. Current Topics in Medicinal Chemistry. 2: 303-23. PMID 11944822 DOI: 10.2174/1568026023394281  0.457
2002 Walters CE, Pryce G, Hankey DJ, Sebti SM, Hamilton AD, Baker D, Greenwood J, Adamson P. Inhibition of Rho GTPases with protein prenyltransferase inhibitors prevents leukocyte recruitment to the central nervous system and attenuates clinical signs of disease in an animal model of multiple sclerosis. Journal of Immunology (Baltimore, Md. : 1950). 168: 4087-94. PMID 11937568 DOI: 10.4049/Jimmunol.168.8.4087  0.354
2002 Arteaga CL, Khuri F, Krystal G, Sebti S. Overview of rationale and clinical trials with signal transduction inhibitors in lung cancer. Seminars in Oncology. 29: 15-26. PMID 11894010 DOI: 10.1053/Sonc.2002.31524  0.303
2002 Li X, Liu L, Tupper JC, Bannerman DD, Winn RK, Sebti SM, Hamilton AD, Harlan JM. Inhibition of protein geranylgeranylation and RhoA/RhoA kinase pathway induces apoptosis in human endothelial cells. The Journal of Biological Chemistry. 277: 15309-16. PMID 11839765 DOI: 10.1074/Jbc.M201253200  0.443
2002 Ohkanda J, Lockman JW, Kothare MA, Qian Y, Blaskovich MA, Sebti SM, Hamilton AD. Design and synthesis of potent nonpeptidic farnesyltransferase inhibitors based on a terphenyl scaffold. Journal of Medicinal Chemistry. 45: 177-88. PMID 11754590 DOI: 10.1021/Jm0103099  0.351
2002 Adnane J, Seijo E, Chen Z, Bizouarn F, Leal M, Sebti SM, Muñoz-Antonia T. Rhob, not RhoA, represses the transcription of the transforming growth factor β type II receptor by a mechanism involving activator protein 1 Journal of Biological Chemistry. 277: 8500-8507. PMID 11741970 DOI: 10.1074/Jbc.M104367200  0.359
2001 Kucich U, Rosenbloom JC, Herrick DJ, Abrams WR, Hamilton AD, Sebti SM, Rosenbloom J. Signaling events required for transforming growth factor-beta stimulation of connective tissue growth factor expression by cultured human lung fibroblasts. Archives of Biochemistry and Biophysics. 395: 103-12. PMID 11673871 DOI: 10.1006/Abbi.2001.2571  0.335
2001 Delarue FL, Taylor BS, Sebti SM. Ras and RhoA suppress whereas RhoB enhances cytokine-induced transcription of nitric oxide synthase-2 in human normal liver AKN-1 cells and lung cancer A-549 cells Oncogene. 20: 6531-6537. PMID 11641777 DOI: 10.1038/Sj.Onc.1204801  0.405
2001 Turkson J, Ryan D, Kim JS, Zhang Y, Chen Z, Haura E, Laudano A, Sebti S, Hamilton AD, Jove R. Phosphotyrosyl peptides block Stat3-mediated DNA binding activity, gene regulation, and cell transformation. The Journal of Biological Chemistry. 276: 45443-55. PMID 11579100 DOI: 10.1074/Jbc.M107527200  0.354
2001 Finder JD, Petrus JL, Hamilton A, Villavicencio RT, Pitt BR, Sebti SM. Signal transduction pathways of IL-1beta-mediated iNOS in pulmonary vascular smooth muscle cells. American Journal of Physiology. Lung Cellular and Molecular Physiology. 281: L816-23. PMID 11557585 DOI: 10.1152/Ajplung.2001.281.4.L816  0.324
2001 Teng S, Sun J, Irby R, Hamilton AD, Sebti S, Yeatman TJ. v-Src transformation is mediated through farnesylated proteins. The Journal of Surgical Research. 99: 343-6. PMID 11469908 DOI: 10.1006/Jsre.2001.6184  0.402
2001 Ohkanda J, Lockman JW, Yokoyama K, Gelb MH, Croft SL, Kendrick H, Harrell MI, Feagin JE, Blaskovich MA, Sebti SM, Hamilton AD. Peptidomimetic inhibitors of protein farnesyltransferase show potent antimalarial activity. Bioorganic & Medicinal Chemistry Letters. 11: 761-4. PMID 11277514 DOI: 10.1016/S0960-894X(01)00055-5  0.333
2001 Sun J, Nam S, Lee CS, Li B, Coppola D, Hamilton AD, Dou QP, Sebti SM. CEP1612, a dipeptidyl proteasome inhibitor, induces p21WAF1 and p27KIP1 expression and apoptosis and inhibits the growth of the human lung adenocarcinoma A-549 in nude mice. Cancer Research. 61: 1280-4. PMID 11245420  0.37
2001 Crespo NC, Ohkanda J, Yen TJ, Hamilton AD, Sebti SM. The farnesyltransferase inhibitor, FTI-2153, blocks bipolar spindle formation and chromosome alignment and causes prometaphase accumulation during mitosis of human lung cancer cells. The Journal of Biological Chemistry. 276: 16161-7. PMID 11154688 DOI: 10.1074/jbc.M006213200  0.722
2000 Sebti SM, Hamilton AD. Farnesyltransferase and geranylgeranyltransferase I inhibitors and cancer therapy: lessons from mechanism and bench-to-bedside translational studies. Oncogene. 19: 6584-93. PMID 11426643 DOI: 10.1038/Sj.Onc.1204146  0.401
2000 Sebti SM, Hamilton AD. Design of growth factor antagonists with antiangiogenic and antitumor properties. Oncogene. 19: 6566-73. PMID 11426641 DOI: 10.1038/Sj.Onc.1204121  0.391
2000 Adnane J, Bizouarn FA, Chen Z, Ohkanda J, Hamilton AD, Munoz-Antonia T, Sebti SM. Inhibition of farnesyltransferase increases TGFbeta type II receptor expression and enhances the responsiveness of human cancer cells to TGFbeta. Oncogene. 19: 5525-33. PMID 11114730 DOI: 10.1038/Sj.Onc.1203920  0.455
2000 Sebti SM, Hamilton AD. Farnesyltransferase and geranylgeranyltransferase I inhibitors in cancer therapy: important mechanistic and bench to bedside issues. Expert Opinion On Investigational Drugs. 9: 2767-82. PMID 11093352 DOI: 10.1517/13543784.9.12.2767  0.412
2000 Dey A, She H, Kim L, Boruch A, Guris DL, Carlberg K, Sebti SM, Woodley DT, Imamoto A, Li W. Colony-stimulating factor-1 receptor utilizes multiple signaling pathways to induce cyclin D2 expression Molecular Biology of the Cell. 11: 3835-3848. PMID 11071910 DOI: 10.1091/Mbc.11.11.3835  0.346
2000 Sebti SM, Hamilton AD. Inhibition of Rho GTPases using protein geranylgeranyltransferase I inhibitors. Methods in Enzymology. 325: 381-8. PMID 11036620 DOI: 10.1016/S0076-6879(00)25459-1  0.417
2000 Wei S, Gilvary DL, Corliss BC, Sebti S, Sun J, Straus DB, Leibson PJ, Trapani JA, Hamilton AD, Weber MJ, Djeu JY. Direct tumor lysis by NK cells uses a Ras-independent mitogen-activated protein kinase signal pathway. Journal of Immunology (Baltimore, Md. : 1950). 165: 3811-9. PMID 11034387 DOI: 10.4049/Jimmunol.165.7.3811  0.426
2000 Blaskovich MA, Lin Q, Delarue FL, Sun J, Park HS, Coppola D, Hamilton AD, Sebti SM. Design of GFB-111, a platelet-derived growth factor binding molecule with antiangiogenic and anticancer activity against human tumors in mice. Nature Biotechnology. 18: 1065-70. PMID 11017044 DOI: 10.1038/80257  0.309
2000 Coxon FP, Helfrich MH, Hof RV, Sebti S, Ralston SH, Hamilton A, Rogers MJ. Protein geranylgeranylation is required for osteoclast formation, function, and survival: inhibition by bisphosphonates and GGTI-298. Journal of Bone and Mineral Research. 15: 1467-1476. PMID 10934645 DOI: 10.1359/Jbmr.2000.15.8.1467  0.321
2000 Cohen-Jonathan E, Muschel RJ, Gillies McKenna W, Evans SM, Cerniglia G, Mick R, Kusewitt D, Sebti SM, Hamilton AD, Oliff A, Kohl N, Gibbs JB, Bernhard EJ. Farnesyltransferase inhibitors potentiate the antitumor effect of radiation on a human tumor xenograft expressing activated HRAS. Radiation Research. 154: 125-32. PMID 10931682 DOI: 10.1667/0033-7587(2000)154[0125:Fiptae]2.0.Co;2  0.414
2000 Allal C, Favre G, Couderc B, Salicio S, Sixou S, Hamilton AD, Sebti SM, Lajoie-Mazenc I, Pradines A. RhoA prenylation is required for promotion of cell growth and transformation and cytoskeleton organization but not for induction of serum response element transcription. The Journal of Biological Chemistry. 275: 31001-8. PMID 10896672 DOI: 10.1074/Jbc.M005264200  0.399
2000 Chen Z, Sun J, Pradines A, Favre G, Adnane J, Sebti SM. Both farnesylated and geranylgeranylated RhoB inhibit malignant transformation and suppress human tumor growth in nude mice Journal of Biological Chemistry. 275: 17974-17978. PMID 10770919 DOI: 10.1074/jbc.C000145200  0.328
2000 Kucich U, Rosenbloom JC, Shen G, Abrams WR, Hamilton AD, Sebti SM, Rosenbloom J. TGF-beta1 stimulation of fibronectin transcription in cultured human lung fibroblasts requires active geranylgeranyl transferase I, phosphatidylcholine-specific phospholipase C, protein kinase C-delta, and p38, but not erk1/erk2. Archives of Biochemistry and Biophysics. 374: 313-24. PMID 10666313 DOI: 10.1006/Abbi.1999.1625  0.349
2000 Boota A, Johnson B, Lee KL, Blaskovich MA, Liu SX, Kagan VE, Hamilton A, Pitt B, Sebti SM, Davies P. Prenyltransferase inhibitors block superoxide production by pulmonary vascular smooth muscle American Journal of Physiology - Lung Cellular and Molecular Physiology. 278. PMID 10666117 DOI: 10.1152/Ajplung.2000.278.2.L329  0.318
2000 Carloni V, Pinzani M, Giusti S, Romanelli RG, Parola M, Bellomo G, Failli P, Hamilton AD, Sebti SM, Laffi G, Gentilini P. Tyrosine phosphorylation of focal adhesion kinase by PDGF is dependent on ras in human hepatic stellate cells. Hepatology (Baltimore, Md.). 31: 131-40. PMID 10613738 DOI: 10.1002/Hep.510310121  0.434
2000 Lantry LE, Zhang Z, Yao R, Crist KA, Wang Y, Ohkanda J, Hamilton AD, Sebti SM, Lubet RA, You M. Effect of farnesyltransferase inhibitor FTI-276 on established lung adenomas from A/J mice induced by 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone. Carcinogenesis. 21: 113-6. PMID 10607742 DOI: 10.1093/Carcin/21.1.113  0.376
2000 Jiang K, Coppola D, Crespo NC, Nicosia SV, Hamilton AD, Sebti SM, Cheng JQ. The phosphoinositide 3-OH kinase/AKT2 pathway as a critical target for farnesyltransferase inhibitor-induced apoptosis. Molecular and Cellular Biology. 20: 139-48. PMID 10594016 DOI: 10.1128/Mcb.20.1.139-148.2000  0.779
2000 Kotharé MA, Ohkanda J, Lockman JW, Qian Y, Blaskovich MA, Sebti SM, Hamilton AD. Development of a Tripeptide Mimetic Strategy for the Inhibition of Protein Farnesyltransferase Tetrahedron. 56: 9833-9841. DOI: 10.1016/S0040-4020(00)00890-5  0.343
1999 Bowman T, Yu H, Sebti S, Dalton W, Jove R. Signal Transducers and Activators of Transcription: Novel Targets for Anticancer Therapeutics. Cancer Control : Journal of the Moffitt Cancer Center. 6: 427-435. PMID 10758575 DOI: 10.1177/107327489900600501  0.374
1999 Qian Y, Marugan JJ, Fossum RD, Vogt A, Sebti SM, Hamilton AD. Probing the hydrophobic pocket of farnesyltransferase: aromatic substitution of CAAX peptidomimetics leads to highly potent inhibitors. Bioorganic & Medicinal Chemistry. 7: 3011-24. PMID 10658608 DOI: 10.1016/S0968-0896(99)00252-7  0.424
1999 Liu L, Moesner P, Kovach NL, Bailey R, Hamilton AD, Sebti SM, Harlan JM. Integrin-dependent leukocyte adhesion involves geranylgeranylated protein(s). The Journal of Biological Chemistry. 274: 33334-40. PMID 10559211 DOI: 10.1074/Jbc.274.47.33334  0.368
1999 Pollack IF, Bredel M, Erff M, Hamilton AD, Sebti SM. Inhibition of Ras and related guanosine triphosphate-dependent proteins as a therapeutic strategy for blocking malignant glioma growth: II--preclinical studies in a nude mouse model. Neurosurgery. 45: 1208-14; discussion . PMID 10549939 DOI: 10.1097/00006123-199911000-00039  0.372
1999 Mazet JL, Padieu M, Osman H, Maume G, Mailliet P, Dereu N, Hamilton AD, Lavelle F, Sebti SM, Maume BF. Combination of the novel farnesyltransferase inhibitor RPR130401 and the geranylgeranyltransferase-1 inhibitor GGTI-298 disrupts MAP kinase activation and G(1)-S transition in Ki-Ras-overexpressing transformed adrenocortical cells. Febs Letters. 460: 235-40. PMID 10544242 DOI: 10.1016/S0014-5793(99)01355-1  0.443
1999 Turkson J, Bowman T, Adnane J, Zhang Y, Djeu JY, Sekharam M, Frank DA, Holzman LB, Wu J, Sebti S, Jove R. Requirement for Ras/Rac1-mediated p38 and c-Jun N-terminal kinase signaling in Stat3 transcriptional activity induced by the Src oncoprotein. Molecular and Cellular Biology. 19: 7519-7528. PMID 10523640 DOI: 10.1128/Mcb.19.11.7519  0.411
1999 Sun J, Blaskovich MA, Knowles D, Qian Y, Ohkanda J, Bailey RD, Hamilton AD, Sebti SM. Antitumor efficacy of a novel class of non-thiol-containing peptidomimetic inhibitors of farnesyltransferase and geranylgeranyltransferase I: Combination therapy with the cytotoxic agents cisplatin, taxol, and gemcitabine Cancer Research. 59: 4919-4926. PMID 10519405  0.316
1999 O'Connor SJ, Barr KJ, Wang L, Sorensen BK, Tasker AS, Sham H, Ng SC, Cohen J, Devine E, Cherian S, Saeed B, Zhang H, Lee JY, Warner R, Tahir S, ... ... Sebti SM, et al. Second-generation peptidomimetic inhibitors of protein farnesyltransferase demonstrating improved cellular potency and significant in vivo efficacy. Journal of Medicinal Chemistry. 42: 3701-10. PMID 10479301 DOI: 10.1021/Jm9901935  0.377
1999 Cohen-Jonathan E, Toulas C, Ader I, Monteil S, Allal C, Bonnet J, Hamilton AD, Sebti SM, Daly-Schveitzer N, Favre G. The farnesyltransferase inhibitor FTI-277 suppresses the 24-kDa FGF2- induced radioresistance in HeLa cells expressing wild-type RAS Radiation Research. 152: 404-411. PMID 10477917 DOI: 10.2307/3580225  0.41
1999 Vasudevan A, Qian Y, Vogt A, Blaskovich MA, Ohkanda J, Sebti SM, Hamilton AD. Potent, highly selective, and non-thiol inhibitors of protein geranylgeranyltransferase-I Journal of Medicinal Chemistry. 42: 1333-1340. PMID 10212118 DOI: 10.1021/Jm9900873  0.373
1999 Sun J, Qian Y, Chen Z, Marfurt J, Hamilton AD, Sebti SM. The geranylgeranyltransferase I inhibitor GGTI-298 induces hypophosphorylation of retinoblastoma and partner switching of cyclin- dependent kinase inhibitors: A potential mechanism for GGTI-298 antitumor activity Journal of Biological Chemistry. 274: 6930-6934. PMID 10066746 DOI: 10.1074/Jbc.274.11.6930  0.464
1999 Cohen Jonathan-Moyal E, Muschel R, McKenna W, Hamilton A, Sebti S, Gibbs J, Oliff A, Cerniglia G, Mick R, Bernhard E. 33 In vivo radiosensitization of human tumors expressing mutant ras by farnesyltransferase inhibitors International Journal of Radiation Oncology*Biology*Physics. 45: 163-164. DOI: 10.1016/S0360-3016(99)90051-2  0.398
1998 Adnane J, Bizouarn FA, Qian Y, Hamilton AD, Sebti SM. p21(WAF1/CIP1) is upregulated by the geranylgeranyltransferase I inhibitor GGTI-298 through a transforming growth factor β- and Sp1- responsive element: Involvement of the small GTPase RhoA Molecular and Cellular Biology. 18: 6962-6970. PMID 9819384 DOI: 10.1128/Mcb.18.12.6962  0.387
1998 Kucich U, Rosenbloom JC, Shen G, Abrams WR, Blaskovich MA, Hamilton AD, Ohkanda J, Sebti SM, Rosenbloom J. Requirement for geranylgeranyl transferase I and acyl transferase in the TGF-β-stimulated pathway leading to elastin mRNA stabilization Biochemical and Biophysical Research Communications. 252: 111-116. PMID 9813154 DOI: 10.1006/Bbrc.1998.9544  0.347
1998 Stark WW, Blaskovich MA, Johnson BA, Qian Y, Vasudevan A, Pitt B, Hamilton AD, Sebti SM, Davies P. Inhibiting geranylgeranylation blocks growth and promotes apoptosis in pulmonary vascular smooth muscle cells American Journal of Physiology - Lung Cellular and Molecular Physiology. 275. PMID 9688935 DOI: 10.1152/Ajplung.1998.275.1.L55  0.429
1998 Bredel M, Pollack IF, Freund JM, Hamilton AD, Sebti SM. Inhibition of Ras and related G-proteins as a therapeutic strategy for blocking malignant glioma growth Neurosurgery. 43: 124-132. PMID 9657198 DOI: 10.1097/00006123-199807000-00081  0.461
1998 Qian Y, Vogt A, Vasudevan A, Sebti SM, Hamilton AD. Selective inhibition of type-I geranylgeranyltransferase in vitro and in whole cells by CAAL peptidomimetics Bioorganic and Medicinal Chemistry. 6: 293-299. PMID 9568283 DOI: 10.1016/S0968-0896(97)10040-2  0.306
1998 Sun J, Qian Y, Hamilton AD, Sebti SM. Both farnesyltransferase and geranylgeranyltransferase I inhibitors are required for inhibition of oncogenic K-Ras prenylation but each alone is sufficient to suppress human tumor growth in node mouse xenografts Oncogene. 16: 1467-1473. PMID 9525745 DOI: 10.1038/Sj.Onc.1201656  0.435
1998 Sebti SM, Hamilton AD. New approaches to anticancer drug design based on the inhibition of farnesyltransferase Drug Discovery Today. 3: 26-33. DOI: 10.1016/S1359-6446(97)01122-7  0.42
1998 McKenna WG, Wu JM, Hamilton AD, Sebti SM, Muschel RJ, Bernhard EJ. Prenyltransferase inhibitors as radiosensitizing agents for tumor cells with activated ras International Journal of Radiation Oncology*Biology*Physics. 42: 190. DOI: 10.1016/S0360-3016(98)80233-2  0.413
1997 Sebti SM, Hamilton AD. Anticancer activity of farnesyltransferase and geranylgeranyltransferase I inhibitors: prospects for drug development. Expert Opinion On Investigational Drugs. 6: 1711-4. PMID 15989575 DOI: 10.1517/13543784.6.11.1711  0.42
1997 Vogt A, Sun J, Qian Y, Hamilton AD, Sebti SM. The geranylgeranyltransferase-I inhibitor GGTI-298 arrests human tumor cells in G0/G1 and induces p21(WAF1/CIP1/SD11) in a p53-independent manner Journal of Biological Chemistry. 272: 27224-27229. PMID 9341167 DOI: 10.1074/Jbc.272.43.27224  0.409
1997 Sebti SM, Hamilton AD. Inhibition of Ras prenylation: A novel approach to cancer chemotherapy Pharmacology and Therapeutics. 74: 103-114. PMID 9336018 DOI: 10.1016/S0163-7258(97)00014-4  0.337
1997 Lerner EC, Zhang TT, Knowles DB, Qian Y, Hamilton AD, Sebti SM. Inhibition of the prenylation of K-Ras, but not H- or N-Ras, is highly resistant to CAAX peptidomimetics and requires both a farnesyltransferase and a geranylgeranyltransferase I inhibitor in human tumor cell lines Oncogene. 15: 1283-1288. PMID 9315095 DOI: 10.1038/Sj.Onc.1201296  0.302
1997 Lerner EC, Hamilton AD, Sebti SM. Inhibition of Ras prenylation: A signaling target for novel anti-cancer drug design Anti-Cancer Drug Design. 12: 229-238. PMID 9199657  0.324
1997 Qian Y, Sebti SM, Hamilton AD. Farnesyltransferase as a target for anticancer drug design Biopolymers. 43: 25-41. PMID 9174410 DOI: 10.1002/(Sici)1097-0282(1997)43:1<25::Aid-Bip4>3.0.Co;2-2  0.342
1997 Clark GJ, Kinch MS, Rogers-Graham K, Sebti SM, Hamilton AD, Der CJ. The Ras-related protein Rheb is farnesylated and antagonizes Ras signaling and transformation Journal of Biological Chemistry. 272: 10608-10615. PMID 9099708 DOI: 10.1074/Jbc.272.16.10608  0.363
1997 McGuire TF, Sebti SM. Geranylgeraniol potentiates lovastatin inhibition of oncogenic H-Ras processing and signaling while preventing cytotoxicity Oncogene. 14: 305-312. PMID 9018116 DOI: 10.1038/Sj.Onc.1200819  0.426
1997 Pollack IF, Bredel M, Freund JM, Sebti SM. Inhibition of malignant glioma growth by blocking p21RAS processing Clinical Neurology and Neurosurgery. 99. DOI: 10.1016/S0303-8467(97)82340-2  0.351
1996 McGuire TF, Qian Y, Vogt A, Hamilton AD, Sebti SM. Platelet-derived growth factor receptor tyrosine phosphorylation requires protein geranylgeranylation but not farnesylation Journal of Biological Chemistry. 271: 27402-27407. PMID 8910319 DOI: 10.1074/Jbc.271.44.27402  0.391
1996 Pei Z, Sebti SM. Cys 102 and His 398 are required for bleomycin-inactivating activity but not for hexamer formation of yeast bleomycin hydrolase Biochemistry. 35: 10751-10756. PMID 8718865 DOI: 10.1021/Bi9605447  0.303
1995 Vogt A, Qian Y, Blaskovich MA, Fossum RD, Hamilton AD, Sebti SM. A non-peptide mimetic of Ras-CAAX: Selective inhibition of farnesyltransferase and Ras processing Journal of Biological Chemistry. 270: 660-664. PMID 7822292 DOI: 10.1074/Jbc.270.2.660  0.362
1995 Sun J, Sebti SM, Qian Y, Hamilton AD. Ras CAAX Peptidomimetic FTI 276 Selectively Blocks Tumor Growth in Nude Mice of a Human Lung Carcinoma with K-Ras Mutation and p53 Deletion Cancer Research. 55: 4243-4247. PMID 7671229  0.338
1995 Lernert EC, Qian Y, Hamilton AD, Sebti SM. Disruption of oncogenic K-Ras4B processing and signaling by a potent geranylgeranyltransferase I inhibitor Journal of Biological Chemistry. 270: 26770-26773. PMID 7592913 DOI: 10.1074/Jbc.270.45.26770  0.391
1995 Sebti SM. Burkitt lymphoma daudi cells contain two distinct farnesyltransferases with different divalent cation requirements Biochemistry. 34: 12398-12403. PMID 7547984 DOI: 10.1021/Bi00038A037  0.318
1995 Kauffmann RC, Qian Y, Vogt A, Sebti SM, Hamilton AD, Carthew RW. Activated Drosophila Ras1 is selectively suppressed by isoprenyl transferase inhibitors. Proceedings of the National Academy of Sciences of the United States of America. 92: 10919-23. PMID 7479910 DOI: 10.1073/Pnas.92.24.10919  0.334
1985 Sebti SM, Moynihan CG, Anderson JN, Baird WM. Benzo[a]pyrene-dna adduct formation in target and activator cells in a wistar rat embryo cell-mediated v79 cell mutation assay Carcinogenesis. 6: 983-988. PMID 4017178 DOI: 10.1093/Carcin/6.7.983  0.303
Show low-probability matches.